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ABCA ATP-binding cassette transporter sub-family A
ABCB ATP-binding cassette transporter sub-family B
ABCC ATP-binding cassette transporter sub-family C
ABCG ATP-binding cassette transporter sub-family G
ACAT2 Acyl-coenzyme A:cholesterol acyltransferase
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AST Aspartate aminotransferase
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BAIF Bile acid-independent fraction
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BE Biliary excretion
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DR4 Direct repeat spaced by four nucleotides
DMEM Dulbecco’s modified Eagle’s medium
EE Ethinylestradiol
EGCG Epigallocatechin gallate
ERK Extracellular signal-regulated kinase
FASN Fatty acid synthase
FGF Fibroblast growth factor
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FGFR Fibroblast growth factor receptor
FXR Farnesoid X receptor
HDL High density lipoprotein
HMG-CoA 3-Hydroxy-3-methyl-glutaryl-coenzyme A
HNF Hepatocyte nuclear factor
HPLC High performance liquid chromatography
IBABP Ileal bile acid binding protein
IR1 Inverted repeat spaced by one nucleotide
JNK Jun N-terminal kinase
LDH Lactate dehydrogenase
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LRH-1 Liver receptor homologue-1
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MAPK Mitogen-activated protein kinase
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NRF2 Nuclear factor (erythroid-derived 2)-like 2
NTCP Na+-taurocholate cotransporting polypeptide
OATP Organic anion transporting polypeptide
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SLC Solute carrier
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Bile production represents one of the essential functions of the liver. Firstly, bile plays
a vital role in digestion and absorption of lipids in the intestine. Secondly, bile serves for
elimination of endogenous compounds and their metabolites, such as bilirubin, cholesterol,
and hormones. Moreover, bile also provides an important excretory route for exogenous
substances, toxins, drugs and their metabolites (Kuntz and Kuntz, 2008).
Bile components are primarily secreted by hepatocytes into bile canaliculi that
eventually merge and form bile ductules. Primary bile is further modified by cholangiocyte
secretion and absorption as it passes through the bile ductules and ducts. Bile production is
driven by osmotic gradient formed by a continuous secretion of organic solutes from the
hepatocytes into the bile canaliculi, followed by passive movement of water. Bile flow has
two major components: bile acid-dependent fraction (BADF) and bile acid-independent
fraction (BAIF). BADF is mainly based on the vectorial transport of bile acids from the
sinusoidal blood to bile. BAIF is mainly generated by biliary secretion of glutathione.
Cholangiocyte secretion of bicarbonate also contributes to the bile acid-independent
mechanism, although this varies with the species and responses to enteric hormones
(Trauner and Boyer, 2003). In humans, approximately 450 mL of primary bile is formed
every day by equal contribution of both BADF and BAIF. The volume of hepatic bile is
further increased by approximately 150 mL by cholangiocyte active secretion, which
results in formation of so-called ductular (hepatic) bile (Kuntz and Kuntz, 2008).
Bile is an isotonic aqueous solution (~97% water) containing bile acids,
phospholipids (predominantly phosphatidylcholine), cholesterol, bilirubin, glutathione,
proteins, and inorganic ions (Fig. 1). Bile also contains minute amounts of antibodies and
hormones. Being an aqueous solution, bile is more suitable for excretion of hydrophilic
compounds.  However,  the  presence  of  micelle  forming  bile  acids  above  their  critical
micellar concentration allows solubilization of lipids in bile. Thus, water-soluble as well as
lipid-soluble compounds are excreted via bile.
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Figure 1. Schematic chart representing composition of human hepatic bile. Adapted from Kuntz and Kuntz
(2008).
In human bile, the concentrations of individual constituents range from being
slightly higher than in plasma (e.g., electrolytes except for chlorides, which are slightly
lower) to being extremely concentrated such as bile acids (2-45 mM) and bilirubin
(0.5-2 g/L) (Esteller, 2008). Human bile is also rich in lipids as the concentrations of
cholesterol and phospholipids stretch between 0.6-3.2 g/L and 0.25-8.1 g/L, respectively.
Bile acids together with cholesterol and phospholipids form mixed micelles in bile and the
ratio between these three constituents is important for cholesterol solubility (Fig. 2).
Imbalance in this ratio may raise propensity for gallstone formation.
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Figure 2. Equilibrium bile acid-phospholipid-cholesterol phase diagram. There are three types of solid
particles that can be formed in the bile. These are crystals, micelles and vesicles. Area A is one-phase zone
containing micelles only (cholesterol is completely soluble). Area B represents two-phase zone with micelles
and crystals of cholesterol. Area C represents three-phase zone containing micelles, vesicles and crystal of
cholesterol. Area D represents two-phase zone with micelles and vesicles. The bile components are expressed
in mol percent. Adapted from a review article by Venneman and van Erpecum (2010).
1.1.1. Biliary bile acid excretion
Hepatocytes are polarized cells in which three different compartments of plasma
membrane can be distinguished based on structural and functional characteristics. About
37% of plasma membrane (sinusoidal membrane) is in direct contact with Disse’s space
and mediates exchange of compounds between blood and hepatocytes. Bile secretory pole
of the hepatocyte is represented by canalicular (apical) membrane, which accounts for 15%
of the cell membrane. The remaining 50% of total cell surface forms lateral membrane
with specialized structures allowing adhesion (desmosomes and tight-junctions) and
communication (gap-junctions) between neighboring hepatocytes (Kuntz and Kuntz,
2008). Hepatocyte sinusoidal membrane together with lateral membrane is often
designated as basolateral membrane.
Biliary excretion of bile acids is an active process involving a number of transport
systems at both the basolateral and canalicular membranes of hepatocytes. Basolateral
transporters are particularly important for bile formation since more than 95% of bile acids
secreted into bile undergo enterohepatic recirculation. While unconjugated bile acids can
penetrate through plasma membrane by passive diffusion (as weak acids they are
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uncharged at physiological pH), bile acids conjugated with glycine or taurine require active
transport systems for crossing plasma membrane. Basolateral hepatocyte uptake is directed
against a concentration gradient between the portal blood and hepatocyte cytosol and is
mediated by either sodium-dependent or sodium-independent mechanisms (Esteller, 2008).
Following basolateral uptake, bile acids are transferred to the apical pole and excreted
across the apical membrane into canalicular space. Canalicular excretion of bile acids is
also an energy-dependent process as it takes place against a high concentration gradient.
Because the capacity of bile acid basolateral uptake is 8-10 higher than the secretion rate at
the canalicular membrane, the transport across the canalicular membrane is the rate-
limiting step in biliary bile acid excretion (Kuntz and Kuntz, 2008).
Although the amount of bile acids secreted in bile correlates with the volume of
osmotically secreted water, there is a significant variability in choleretic activity of
individual bile acids. In general, monohydroxy bile acids function cholestatically, while
dihydroxy and trihydroxy bile acids (see Fig. 3) have a choleretic effect. Some bile acids,
especially ursodeoxycholic acid and its nor-derivatives, generate a volume of bile that is
higher than it would be expected from their actual osmotic activity. It seems that such
hypercholeresis is a result of their early reabsorption in cholangiocytes and immediate re-
secretion by hepatocytes. This phenomenon has been termed the cholehepatic shunt
pathway (Esteller, 2008).
1.1.1.1. Bile acid synthesis
Although bile acid pool undergoes extensive enterohepatic recirculation, a considerable
amount of bile acids is loss through fecal excretion. Thus, de novo bile acid synthesis in the
liver compensates for this bile acid loss. In humans, about 500 mg of bile acids are
synthesized every day (Russell, 2003). Primary bile acids, cholic acid and
chenodeoxycholic acid, are synthesized from cholesterol exclusively in the liver via two
independent pathways, i.e., classic (neutral) and alternative (acidic) pathway (Fig. 3). The
classic and alternative pathways are also designated as neutral and acidic, respectively,
since the intermediates are either neutral sterols or carboxylic acids. At least 14 enzymes
have been shown to take part in the bile acid synthesis (Chiang, 2009). Among these,
cholesterol 7α-hydroxylase (CYP7A1) is a critical enzyme as it catalyzes the first and rate-
limiting step of the classic pathway, which accounts for ~90% of bile acid synthesis in
humans. CYP7A1 catalyzes hydroxylation of cholesterol into 7α-hydroxycholesterol,
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which is then converted into 7α-hydroxy-4-cholesten-3-on (C4). Interestingly, plasma
concentration of C4 has been identified as a reliable marker of CYP7A1/Cyp7a1 activity
both in humans and laboratory animals (Axelson et al., 1991; Galman et al., 2003). In the
liver, C4 is then metabolized into either cholic acid or chenodeoxycholic acid depending
on the activity of sterol 12α-hydroxylase (CYP8B1). CYP8B1 activity, which favors cholic
acid synthesis, thus determines the ratio between production of cholic acid and
chenodeoxycholic acid. The alternative pathway is initiated by sterol 27-hydroxylase
(CYP27A1) and leads selectively to the synthesis of chenodeoxycholic acid (Chiang,
2009).
Bile  acid  synthesis  within  the  liver  is  completed  when  primary  bile  acids  are
conjugated to taurine or glycine. The conjugation is catalyzed by bile acid:CoA synthase
and bile acid:amino acid transferase. Primary bile acids that escape absorption in the small
intestine are then converted to secondary bile acids, deoxycholic acid and lithocholic acid.
The conversion involves deconjugation and removal of 7α-hydroxyl from the primary bile
acids by intestinal bacteria. A certain amount of secondary bile acids is also reabsorbed
and returns to the liver, the rest is excreted in feces. Further metabolism of secondary bile
acids in the liver or intestine yields tertiary bile acids, such as ursodeoxycholic acid and
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Figure 3. Schematic diagram showing bile acid synthesis. Bile acids are synthesized from cholesterol in the
liver via two general pathways: the classic (neutral) pathway and the alternative (acidic) pathway. In humans,
bile acid synthesis mainly produces two primary bile acids, cholic acid and chenodeoxycholic acid.
Cholesterol 7α-hydroxylase (CYP7A1) catalyzes the first and rate-limiting step in the classic pathway while
converting cholesterol into 7α-hydroxycholesterol. Sterol 27-hydroxylase (CYP27A1) initiates the alternative
pathway by converting cholesterol into 27-hydroxycholesterol, which is then hydroxylated at 7α-position by
oxysterol 7α-hydroxylase (CYP7B1). In the intestine, cholic acid and chenodeoxycholic acid are
dehydroxylated at the 7α-position by bacterial enzymes to produce deoxycholic acid and lithocholic acid,
respectively (secondary bile acids). Secondary bile acids can be transformed by further metabolism into
tertiary bile acids, such as ursodeoxycholic acid and sulfolithocholic acid. Adapted from Chiang (2009) and






Regulation of bile acid synthesis
Bile acid synthesis in the liver is very tightly regulated since imbalance in bile acid
homeostasis leads to a variety of hepatobiliary and intestinal disorders, such as cholestasis,
gallstone formation, inflammatory bowel disease, etc. (Zhu et al., 2011). Bile acid
synthesis is mainly regulated by feedback suppression of the key enzyme CYP7A1 by
nuclear receptors and inflammatory cytokines.
Under normal conditions, activation of farnesoid X receptor (FXR) is the main
mechanism of suppression of bile acid synthesis (Fig. 4). FXR functions as a sensor for
intracellular levels of bile acids, which are endogenous ligands of this receptor. Especially
hydrophobic bile acids have a potent FXR agonistic activity (Zhu et al., 2011). Both free
and conjugated bile acids bind to the ligand binding domain of FXR, which in turn forms
a heterodimer with retinoid X receptor (RXR). This FXR/RXR complex then binds to the
inverted repeat of AGGTCA-like sequence with one nucleotide spacing (IR1) located in
the promoter regions of FXR target genes to initiate gene transcription. To suppress
CYP7A1 gene expression, activated FRX induces expression of small heterodimeric
partner (SHP), which in turn inhibits activity of hepatocyte nuclear factor-4 alpha (HNF4α)
and liver receptor homologue-1 (LRH-1), which mediate CYP7A1 transcription (Chiang,
2009).
Experiments with Shp knockout mice have pointed out existence of Shp-
independent repression of Cyp7a1 by bile acids (Kerr et al., 2002). Bile acid-induced
secretion of pro-inflammatory cytokines stimulates mitogen-activated protein kinase
(MAPK) cascade leading to activation of JNK (Jun N-terminal kinase), which may inhibit
HNF-4α activity. In addition, pregnane X receptor (PXR) and vitamin D receptor (VDR)
may also suppress CYP7A1 transcription by Shp-independent mechanism (Chiang, 2009).
Gene expression of CYP7A1 is further modulated by fibroblast growth factor 19
(FGF19) or its orthologue Fgf15 in rodents. FGF19/Fgf15 is produced in the intestine
following FXR activation by bile acids and is secreted into the portal blood to regulate bile
acid synthesis in the liver (Inagaki et al., 2005). Released Fgf15 binds to the liver-specific
receptor Fgfr4 (fibroblast growth factor receptor 4) and activate signaling pathways such as
JNK or ERK (extracellular signal-regulated kinase). It has been shown that intestinal
Fxr/Fgf15/Fgfr4 pathway plays a critical role in Cyp7a1 gene suppression in mice
compared to hepatic Fxr/Shp pathway, which had minor effect on Cyp7a1 (Kong et al.,
2012). In addition, human (but not mouse) hepatocytes are also able to express and secrete
FGF19, which exerts its effect on CYP7A1 transcription by an autocrine or paracrine
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mechanism (Song et al., 2009).
Figure 4. Regulation of bile acid homeostasis by farnesoid X receptor (Fxr). In the ileum, bile acids are
reabsorbed by the activity of apical sodium-dependent bile acid transporter (Asbt) located to the brush border
membrane. Under physiological conditions, bile acids within enterocytes activate Fxr that induces production
of intestinal hormone fibroblast growth factor 15 (Fgf15). Fgf15 travels via the portal blood to the liver
where it activates Fgfr4 (fibroblast growth factor receptor 4). Fgf15 binding to Fgfr4 activates signaling
cascades such as Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK), which then
suppress the transcription of cholesterol 7α-hydroxylase (Cyp7a1) gene. Fxr also induces bile acid transport
in both the liver and intestine. In hepatocytes, Fxr stimulates expression of bile salt export pump (Bsep), the
main canalicular bile acid transporter. In enterocytes, Fxr induces expression of ileal bile acid binding protein
(Ibabp) and organic solute transporter (Ost) α and β, which promotes enterohepatic recirculation of bile acids.
Under cholestatic conditions, increased bile acids in the liver activate Fxr as well as other signaling
pathways. Liver Fxr activation triggers transcription of small heterodimeric partner (Shp), which, in turn,
represses transcription of Cyp7a1 and Na+-taurocholate cotransporting polypeptide (Ntcp). At the same time,
activated Fxr induces Ostα/β to promote bile acid efflux from the hepatocytes to the sinusoidal blood.
Adapted from Zhu et al. (2011).
In rodents, but not in humans, Cyp7a1 expression can be induced by activation of
liver X receptor α (Lxrα) (Goodwin et al., 2003). Once activated, Lxrα binds to a putative
bile acid response element (BARE-I), which contains a DR4 (direct repeat spaced by four
nucleotides) motif. DR4 motif Cyp7a1 promoter is conserved in many species but not in
humans. Thus, in contrast to rodents, human CYP7A1 gene promoter is not affected by
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LXRα activation (Chen et al., 2002). Increased bile acid synthesis via Lxrα-mediated
Cyp7a1 induction is thought to be the reason for the relative resistance of rodents to
develop hypercholesterolemia in models of high cholesterol diet. In contrast, Lxrα
knockout mice fed with a cholesterol-enriched diet do not increase bile acid synthesis and
have high liver cholesterol levels compared to wild-types (Peet et al., 1998).
Expression of CYP8B1 is also regulated by bile acid-activated FXR. Mouse
Cyp8b1 can be downregulated by both liver Fxr/Shp and intestinal Fxr/Fgf15/Fgfr4
pathways (Kong et al., 2012). CYP8B1 promoter region also contains sterol response
element and is thus regulated by sterol element-binding proteins (SREBP). SREBP1
increases CYP8B1 transcription and, on the contrary, CYP8B1 gene expression is
suppressed by SREBP2 (Norlin and Wikvall, 2007).
1.1.1.2. Hepatic bile acid transporters
Function of hepatic bile acid transporters is crucial for biliary bile acid excretion.
Na+-taurocholate cotransporting polypeptide (NTCP) mediates sodium-dependent uptake
of bile acids from the sinusoidal blood into hepatocytes. Sodium-independent basolateral
uptake of bile acids is executed by transporters from organic anion transporting
polypeptide (OATP) family. All NTCP and OATPs belong to solute carrier (SLC) family
of transporting proteins. Alternative bile acid efflux from hepatocytes back to blood is
mediated by organic solute transporter alpha and beta (OSTα/β) and transporters from
multidrug resistance-associated protein (MRP) family. Canalicular bile salt export pump
(BSEP) is the major transporter for bile acid excretion into bile (Fig. 5).
Introduction
16
Figure 5. Schematic diagram showing localization of the main bile acid transporters in the hepatocytes.
NTCP, Na+-taurocholate cotransporting polypeptide; OATP, organic anion transporting polypeptide;
OSTα/β, organic solute transporter α/β; BSEP, bile salt export pump; MRP, multidrug resistance-associated
protein.
Na+-taurocholate cotransporting polypeptide
First and foremost, transporter NTCP (encoded by SLC10A1 gene) mediates basolateral
uptake of conjugated bile acids. With a lower affinity, it also transports unconjugated bile
acids. For example, NTCP-mediated transport accounts for more than 80% of taurocholate
uptake, but less than 50% of cholate transport (Trauner and Boyer, 2003). Similarly, NTCP
has a higher affinity to dihydroxy bile acids than to trihydroxy ones (Stieger, 2011). NTCP
utilizes a sodium gradient as a driving force for the transport of bile acids, which is
basically a cotransport of two sodium ions with one bile acid molecule (Hagenbuch and
Meier, 1996). The spectrum of NTCP substrates comprises both endogenous compounds
and xenobiotics, e.g., bromosulfophtalein, dehydroepiandrosterone, estrone-3-sulfate,
triiodo-thyronine, thyroxine, sulindac, and rosuvastatin (Stieger, 2011).
Organic anion transporting polypeptides
OATPs (encoded by SLC genes sub-family 21) represent a large group of transporters with
an important role especially in drug transport. In contrast to NTCP, the transport activity of
OATPs is sodium-independent. Specifically, the bidirectional transport of their substrates
is driven by an antiport of bicarbonate, glutathione or glutathione conjugates (Konig,
2011). The substrate specificity of OATPs is rather broad and embraces a variety of
organic anions and steroid hormones (Konig, 2011). Regarding bile acids, transporters
OATP1A2, OATP1B1, OATP1B3 participate in basolateral uptake in humans; in rodents,
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bile acid uptake is mediated by Oatp1a1, Oatp1a4, Oatp1b2 (Hagenbuch and Meier, 2004).
Multidrug resistance-associated proteins
These transporters belong to the family of ATP-binding cassette (ABC) transporters,
specifically to ABCC sub-family. MRP1 (encoded by ABCC1 gene), MRP3 (ABCC3),
MRP4 (ABCC4), MRP5 (ABCC5) and MRP6 (ABCC6) are localized to the hepatocyte
basolateral membrane and their major role is to efflux endogenous compounds and
xenobiotics from hepatocytes into the sinusoidal blood. With high affinity, MRP1 and
MRP3 transport divalent bile acids, e.g., sulfated taurolithocholate and taurodeoxycholate.
Mrp3 in rodents may also transport monovalent bile acids such as taurocholate and
glycocholate (Keppler, 2011). Expression of MRP3 or MRP4 is low under normal
circumstances but rises in cholestasis or MRP2-deficiency. Their increased expression and
subsequently increased bile acid efflux into blood represent a compensatory mechanism for
defective biliary excretion of bile acids and conjugated bilirubin, which otherwise would
accumulate within the hepatocytes (Zollner and Trauner, 2008). From the whole ABCC
sub-family, the only MRP2 is localized to the hepatocyte canalicular membrane. MRP2
transports compounds such as organic anions, glutathione, bile acids and conjugates with
glutathione, glucuronide and sulfate, as well as unconjugated drugs (methotrexate,
pravastatin, azithromycin) (Keppler, 2011). In the liver, MRP2 provides one of two basic
mechanisms of bile production, i.e., BAIF of bile flow. The importance of its function is
documented by significantly decreased bile production in Mrp2-deficient rats (Ito et al.,
1997; Paulusma et al., 1999) or Mrp2-null mice (Chu et al., 2006). In humans, MRP2
deficiency manifests conjugated hyperbilirubinemia known as Dubin-Johnson syndrome
(Konig et al., 1999). In these patients, MRP3 protein expression is induced to compensate
for the low biliary excretion of organic anions (Zollner and Trauner, 2008).
Organic solute transporters
Heterodimeric complex of Ostα and Ostβ is localized to the basolateral membrane of
hepatocytes. Both subunits are required for plasma membrane localization of the functional
transporter (Soroka et al., 2008). Apart from bile acids, substrates of Ostα/β include
estrone-3-sulfate, dehydroepiandrosteron-3-sulfate, dioxin or prostaglandin E2. Tissue
expression of Ostα/β differs considerably among the species. In mice, these transporters
are barely expressed in the liver, but are abundant in the intestine. Conversely, humans
have higher expression of OSTα/β in the liver than in the intestine (Soroka et al., 2010a).
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Ostα/β is normally expressed at rather low levels but its expression is strongly induced
during cholestatic injury both in humans and rodents. Alternative bile acid efflux by
Ostα/β, similarly to MRP3 and MRP4, helps divert bile acids towards renal excretion under
cholestatic conditions (Zollner and Trauner, 2008). Interestingly, Ostα/β-deficient mice are
protected against cholestasis since the lack of these transporters in the ileum and renal
proximal tubules increases bile acid elimination into feces and urine, respectively (Soroka
et al., 2010b; Soroka et al., 2011).
Bile salt export pump
ATP-dependent BSEP (encoded by ABCB11 gene) is the major canalicular bile acid
transporter which exports bile acids from hepatocytes into bile canaliculi. BSEP transport
activity is the rate limiting-step of biliary bile acid excretion and thus it is primary
responsible for BADF of bile flow (Stieger, 2011). In addition, BSEP mediates biliary
excretion of several drugs, e.g., pravastatin, sulindac, and vinblastine (Funk, 2008).
Estrogen metabolites indirectly decrease BSEP activity by trans-inhibition, i.e., they block
BSEP from the canalicular lumen side after their excretion into bile (Stieger, 2011).
Mutation in the gene encoding BSEP causes progressive familial intrahepatic cholestasis
type 2. Other clinically silent mutations can predispose women to develop intrahepatic
cholestasis of pregnancy (Stieger, 2010).
Regulation of bile acid transporters
Bile acid transporters can be regulated at the level of expression (transcriptional and post-
translational regulation) as well as at the level of transport activity. Regarding the gene
expression, all of above mentioned bile acid transporters are mainly regulated by the
class  II  sub-family  of  the  nuclear  receptor  superfamily.  For  target  gene  regulation,  these
nuclear receptors form a heterodimer with the common binding partner RXR. Their
complex then binds to corresponding nuclear receptor response elements in promoters of
target  genes.  Until  now,  six  nuclear  receptors  from class  II  have  been  shown to  regulate
gene expression of bile acid transporters: FXR, retinoic acid receptor (RAR), PXR,
peroxisome proliferator-activated receptor alpha (PPRAα), constitutive androstane receptor
(CAR), LXRα, and the common partner RXR (Trauner et al., 2011). Other nuclear
receptors involved in bile acid transporter gene regulation are SHP, HNF4α, and LRH-1
(Kosters and Karpen, 2008).
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From all these nuclear receptors, FXR plays the key role in regulation of bile acid
transporters (Fig. 6). In rats, Fxr activation indirectly suppresses Ntcp transcription via
Shp, which interferes with basal Ntcp expression regulated by Rar/Rxr (Kosters and
Karpen, 2008). Shp can reduce Ntcp expression also via repression of Hnf4α and Hnf1α
activity. In contrast, human NTCP promoter does not contain RAR/RXR and HNF4α
response elements. In both humans and rodents, bile acid-activated FXR induces gene
expression of BSEP and OSTα/β. MRP2 expression is also positively regulated by FXR.
Bile acids also activate PXR, CAR and VDR. These nuclear receptors play
important roles in detoxification of bile acids, drugs, and xenobiotics. PXR and CAR have
been shown to induce expression of MRP2/Mrp2 and MRP3/Mrp3. In addition, CAR also
positively regulates expression of MRP4/Mrp4 and VDR induces Mrp3 (Wagner et al.,
2010).  Nuclear  receptors  do  not  exert  their  effects  separately  and  the  final  effect  on
transporter gene expression is a result of a complex cross-talk between several nuclear
receptors (Fig 6).
Figure 6. Gene regulation of hepatic bile acid transporters by nuclear receptors. Arrows represent stimulatory
effect, while dotted lines indicate suppressive effects on the gene expression. Bsep, bile salt export pump;
Car, constitutive androstane receptor; Fxr, farnesoid X receptor; Lxr, liver X receptor; Mdr, multidrug
resistance protein; Mrp, multidrug resistance-associated protein; Ntcp, Na+-taurocholate cotransporting
polypeptide; OST, organic solute transporter; Ppar, peroxisome proliferator-activated receptor; Pxr, pregnane
X receptor; Vdr, vitamin D receptor. Adapted from Zollner and Trauner (2009)
At the level of protein expression, bile acid transporters can be regulated by
phosphorylation/dephosphorylation or altered plasma membrane insertion and endocytic
retrieval. For example, increased cyclic adenosine monophosphate has been shown to
stimulate Ntcp and Bsep insertion into the basolateral and canalicular membrane,
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respectively (Kosters and Karpen, 2008).
Last but not least, a variety of compounds directly modulate the transport activity of
bile acid transporters. Cyclosporine A, for instance, inhibits transport of both Ntcp and
Bsep (Kosters and Karpen, 2008). Another classic example is trans-inhibition of Bsep
activity by estrogens, as mentioned above (Stieger, 2011).
1.1.2. Biliary glutathione excretion
Biliary glutathione excretion represents an important mechanism of bile formation while it
constitutes BAIF of bile flow. Glutathione, both in its reduced and oxidized form, is
excreted into bile via MRP2/Mrp2 in humans and rodents (Fig. 7). The critical role of
Mrp2 in biliary glutathione excretion was first shown in Mrp2-mutant rats (TR– and EHBR
rats), which presented dramatically decreased biliary glutathione output and bile flow
compared to wild-type counterparts (Jemnitz et al., 2010). In Mrp2-deficient mice, biliary
glutathione output is nearly abolished (~6% of wild-type littermates) and bile flow is ~25%
lower than in wild-type mice (Chu et al., 2006).
1.1.2.1. Regulation of biliary glutathione excretion
Expression of MRP2 is known to be regulated at both transcriptional and post-
transcriptional levels. In humans and rodents, it is mainly FXR that takes control over
MRP2 transcription. Additionally, MRP2 transcription is positively regulated by activation
of  CAR and PXR.  Response  elements  of  all  the  above-mentioned  nuclear  receptors  have
been identified within the promoter region of MRP2 gene (Nies and Keppler, 2007). The
post-translational regulation of MRP2 involves both increased insertion of the protein into
the canalicular membrane as well as endocytic retrieval to intracellular pools (Nies and
Keppler, 2007). For instance, clofibrate (Johnson and Klaassen, 2002) and ethinylestradiol




Figure 7. Schematic diagram showing localization of hepatic transporters for glutathione, cholesterol and
phospholipids. MRP, multidrug resistance-associated protein; MDR, multidrug resistance protein; ABCG,
ATP-binding cassette sub-family G, SR-B1, scavenger receptor class B type 1.
1.1.3. Biliary cholesterol excretion
The whole body cholesterol homeostasis is regulated at several levels: cholesterol de novo
synthesis, hepatic catabolism (i.e., bile acid synthesis), intestinal absorption, and biliary
excretion. Under normal circumstances, the amount of cholesterol excreted into bile is
equal to the amount of cholesterol synthesized in the liver and absorbed from the intestine
(Yamanashi et al., 2011), which points towards the importance of biliary cholesterol
excretion.
Biliary  cholesterol  output  is  closely  tied  to  biliary  excretion  of  bile  acids.  Biliary
cholesterol excretion is decreased in the absence of bile acids and, conversely, it is
stimulated after bile acid administration (Oude Elferink et al., 1996). Further, expression
and function of ATP-binding cassette transporters sub-family G (ABCG), multidrug
resistance protein 3 (MDR3) and scavenger receptor class B type 1 (SR-B1) are essential
for cholesterol excretion into bile (Fig. 7).
1.1.3.1. Hepatic cholesterol transporters
ATP-binding cassette transporters sub-family G member 5 and 8
At the hepatocyte canalicular domain, ABCG5 and ABCG8 form a heterodimeric complex
that transports free cholesterol into bile canaliculi. ABCG5/8 complex is also expressed at
the apical membrane of enterocytes and participates in intestinal cholesterol absorption
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(Dikkers and Tietge, 2010). The critical role of ABCG5/8 in biliary cholesterol excretion
has been illustrated by generation of Abcg5/8-deficient mice. Abcg5/8-null mice have
biliary cholesterol output reduced by 80% compared to their littermates (Yu et al., 2002a).
On the contrary, human ABCG5/8 transgenic mice have significantly enhanced cholesterol
excretion into bile, which correlates with the inserted gene copy number and mRNA levels
of ABCG5/8 in the liver of these mice (Yu et al., 2002b).
Scavenger receptor class B type 1
SR-B1 is a selective high density lipoprotein (HDL) receptor at the basolateral membrane
of hepatocytes. It facilitates uptake of esterified cholesterol, which then becomes the main
source of cholesterol excreted into bile (Dikkers and Tietge, 2010). Accordingly, biliary
cholesterol excretion was decreased to nearly ~50% in mice lacking Sr-b1 (Wiersma et al.,
2009). Conversely, hepatic Sr-b1 overexpression enhanced biliary cholesterol output in
these transgenic mice (Kozarsky et al., 1997).
1.1.3.2. Regulation of biliary cholesterol excretion
Nuclear receptor LXRα plays a key role in regulation of biliary cholesterol excretion.
Endogenous ligands of LXRα are oxidized derivatives of cholesterol (oxysterols). Ligand-
activated LXRα forms a heterodimeric complex with RXR and then binds to LXR response
elements within target gene promoters. In the liver, activation of LXRα leads to induction
of Abcg5 and Abcg8 with a consequently increased biliary cholesterol excretion (Repa et
al., 2002). Mice treated with LXRα agonist (T0901317) or fed with high cholesterol diet
showed upregulation of Abcg5/8 and significantly increased biliary cholesterol output
(Plosch et al., 2002). Abcg5/8 transcription is also positively regulated by Lrh-1 and Hnf4α
(Freeman et al., 2004; Sumi et al., 2007).
1.1.4. Biliary phospholipid excretion
MDR3 (or its orthologue Mdr2 in rodents) functions as a flippase of phosphatidylcholine
from the inner to the outer leaflet of hepatocyte canalicular membrane, where
phosphatidylcholine is extracted by bile acids and excreted in bile (Fig. 7). Mdr2 knockout
mice not only lack biliary phosphatidylcholine excretion (Smit et al., 1993), but also
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present significantly decreased biliary excretion of cholesterol (Oude Elferink et al., 1996).
It has been shown that at least minimal amount of phospholipids is needed for normal
cholesterol excretion into bile (Smith et al., 1998).
In humans, mutation in MDR3 gene leads to progressive familial intrahepatic
cholestasis type 1 (Oude Elferink et al., 2006). Heterozygous mutation in MDR3 can
predispose for a variety of liver disorders, such as biliary cirrhosis, drug-induced
cholestasis or cholestasis of pregnancy (Oude Elferink and Beuers, 2011).
1.1.4.1. Regulation of biliary phospholipid excretion
The notion that MDR3 is regulated by FXR arose from the observations in which
hydrophobic, but not hydrophilic, bile acids induced gene expression of Mdr2/MDR3 both
in rodents (Frijters et al., 1997; Gupta et al., 2000) and human hepatocytes (Jung et al.,
2007). Indeed, FXR response element was identified in MDR3/Mdr2 gene promoter and
expression  of  the  transporter  was  inducible  by  treatment  with  a  FXR  agonist  such  as
GW4064 (Huang et al., 2003).
1.1.5. Biliary paracellular transport
Bile components can enter bile canaliculi not only by hepatocyte excretion but also by
paracellular pathway. As mentioned above, there are specialized structures between
adjacent hepatocytes (desmosomes, tight-junctions) to seal the bile canaliculi and to
prevent bile leakage into blood. In particular, tight junctions play a central role in
regulating the movement of solutes, ions and water through the paracellular spaces
between neighboring hepatocytes and forming thus so-called blood-biliary barrier.
Impairment of the blood-biliary barrier function increases paracellular movement of
solutes and causes regurgitation of fluid and electrolytes from bile canaliculi into the blood
(Rahner et al., 1996). This, in turn, can decrease bile flow, as exemplified in estrogen-
treated rats (Elias et al., 1983; Kan et al., 1989). Hence, the proper function of blood-
biliary barrier is considered to play an important role in bile production.
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1.1.6. Drugs and bile formation
A great variety of drugs have been shown to affect bile formation in the sense of both its
decrease (cholestatic effect) and stimulation (choleretic effect). Drugs can trigger
cholestasis by inhibiting hepatic transporter expression and function or, rarely, by inducing
the vanishing bile duct syndrome. In addition, several drugs can induce cholestatic
hepatitis through inflammation and hepatocyte injury. The spectrum of drugs with potential
to induce cholestasis in humans is wide and comprises distinct drug classes such as oral
contraceptives, penicillins, macrolide antibiotics, fluroquinolones, neuroleptics,
nonsteroidal anti-inflammatory drugs and oral antidiabetics (Lindor, 2008). Regarding the
underlying mechanisms of the cholestatic effect, many cases of drug-induced cholestasis
are associated with a functional inhibition of bile acid transporters by the drug itself or its
metabolites. For example, cyclosporine A, rifampicin, bosentan, troglitazone and
glibenclamide inhibit transport activity of BSEP in dose-dependent manner. Estrogen and
progesterone metabolites have been shown to trans-inhibit BSEP function after their
secretion into bile via MRP2. Furthermore, bile production can be also reduced as a result
of decreased expression of the major hepatobiliary transporters. This way estrogen
metabolites decrease bile flow through diminished expression of Mrp2. In addition, genetic
variations in transporter genes can also predispose to drug-induced cholestasis. BSEP and
MDR3 gene polymorphisms and mutations have recently been described in drug-induced
cholestasis (Padda et al., 2011).
Besides drugs, several natural compounds and toxins can also induce cholestasis.
Alpha-naphtylisothiocyanate administration to rats causes chronic cholestatic injury
characterized by bile duct injury and proliferation. Endotoxin administration to rodents
decreases both BADF and BAIF of bile flow through reduced expression or redistribution
of the main bile acid transporters such as Bsep, Ntcp, Oatp and Mrp2 (Rodriguez-Garay,
2003). Further, number of case reports described cholestasis induced by herbal
supplements and infusions. These herbal preparations include Rhamnus Purshiana bark,
Chinese traditional herb Lycopodium Serrated, chaparral leaf, germander extract, comfrey,
grater celandine, and kava root (Lindor, 2008).
On the other side, several drugs and natural compounds have a choleretic effect and
promote bile formation. First of all, dihydroxy (chenodeoxycholic, deoxycholic acid,
ursodeoxycholic acid) and trihydroxy (cholic acid) bile acids exert choleretic effect due to
enhanced biliary bile acid excretion. Some unconjugated dihydroxy acid actually induces
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hypercholeresis, i.e., a choleresis that exceeds predicted values based on the osmotic action
of the secreted bile acid. Hypercholeresis induced by ursodeoxycholic acid or
nor-ursodeoxycholic acid has been attributed to the cholehepatic shunt mechanism, where
the bile acids after their biliary excretion are being reabsorbed by cholangiocytes, returned
to the hepatocyte, and resecreted into bile. By multiple mechanisms, ursodeoxycholic acid
also stimulates expression and function of bile acid transporters and enzymes in bile acid
synthesis and detoxification pathways. For instance, ursodeoxycholic acid promotes
insertion of BSEP and MRP2 into canalicular membrane (Zollner and Trauner, 2008).
Heretofore, ursodeoxycholic acid is the only approved drug for treatment of cholestatic
liver diseases.
Spironolactone and benzylpenicillin have shown capacity to increase BAIF of bile
flow. Spironolactone administration to rats increased biliary glutathione and bicarbonate
secretion, which was associated with increased Mrp2 expression (Ruiz et al., 2005). In
ethinylestradiol-treated rats, spironolactone restored ethinylestradiol-decreased biliary
glutathione secretion and bile flow while increasing Mrp2 protein expression (Ruiz et al.,
2007). Similarly, benzylpenicillin administration to rats also enhanced bile flow and biliary
glutathione output in Mrp2-dependent manner (Ito et al., 2004; Fukami et al., 2011).
 Several herbal choleretic drugs are known from traditional medicine. Cynarine
isolated from artichoke (Cynara scolymus),  curcumin (Curcuma longa) and liquiritigenin
(Glycyrrhiza glabra) are known for their choleretic activity (Speroni et al., 2003).
Curcumin has been shown to increase bile flow during cyclosporine-induced cholestasis in
rats and to enhance both bile flow and biliary glutathione excretion in Mdr2 knockout mice
(Deters et al., 1999; Baghdasaryan et al., 2010). Liquiritigenin, a flavonoid from liquorice,
induced bile flow in rats through both increase in BADF and BAIF (Kim et al., 2009).
Many Chinese traditional herbal medicines are known for their choleretic effect (Sasaki et
al., 1990). Among these, genipin, the main active component of Inchin-ko-to, has been




1.2. Epigallocatechin gallate (EGCG)
For centuries, green tea has been one of the most popular beverages worldwide. Regular
consumption of green tea has been associated with a variety of health benefits. These
purported preventive and therapeutic effects have recently attracted a significant attention
from medical research. Currently, a great amount of research has focused on the role of
green tea intake in prevention of cancer and cardiovascular disease (Yang et al., 2009;
Hodgson and Croft, 2010).
Green tea is very rich in flavonoid compounds. Catechins, which represent the vast
majority of these flavonoids, have been suggested to be responsible for the health
promoting effects of the plant. These catechins make up 30% of the dry weight of green tea
leaves and include EGCG, epigallocatechin, epicatechin gallate, and epicatechin (Wolfram
et al., 2006). EGCG is the most abundant of these compounds (>50% of catechin content)
and  is  generally  considered  to  be  the  major  active  component  of  green  tea  (Nagle  et  al.,
2006; Wolfram et al., 2006). A cup of green tea may contain 100–200 mg of EGCG
(Zaveri, 2006). EGCG is currently a widely used dietary supplement available in numerous
products either in purified form or as a part  of tea or tea extract.  In the weight reduction
supplements, a daily dose of EGCG ranges between 115-270 mg.
Figure 8. Chemical structure of EGCG.
EGCG has demonstrated a wide range of health benefits, which are often related to
its potent antioxidant, anti-inflammatory and anticancer activities (Singh et al., 2011).
EGCG has ability to chelate metal ions and scavenge free oxygen and nitrogen radicals. It
has these properties due to the presence of phenolic groups in rings B and D of its structure
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(see Fig. 8) (Zaveri, 2006). EGCG can exert antioxidant activity also indirectly via
inhibition of redox-sensitive transcription factors such as nuclear factor- κB and activator
protein-1 (Zaveri, 2006). Further, EGCG has been reported to inhibit pro-oxidative
enzymes (lipoxygenase, cyclooxygenase, inducible nitric oxide synthase, xanthine oxidase)
and, conversely, induce antioxidative enzymes and phase II biotransformation enzymes
(glutathione S-transferase and superoxid dismutase) (Frei and Higdon, 2003). In this
induction, transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) seems to
play a pivotal role (Na and Surh, 2008).
1.2.1. EGCG and liver injury
Many experimental studies have shown hepatoprotective action of EGCG in various
models of liver injury. EGCG attenuated development of non-alcoholic steatohepatitis
(Kuzu et al., 2008), liver injury induced by carbon tetrachloride (Yasuda et al., 2009; Tipoe
et al., 2010) or D-galactosamine (Lin et al., 2009) or prevented ischemia/reperfusion-
induced liver apoptosis (Giakoustidis et al., 2010). Most of these effects are ascribed to the
anti-inflammatory  activity  of  EGCG.  Interestingly,  two  studies  have  shown  protective
effect of EGCG against cholestatic liver injury induced by bile duct ligation in mice and
rats (Zhong et al., 2003; Kobayashi et al., 2010).
To date, little is known about the effect of EGCG on biliary physiology or bile acid
homeostasis. Li et al. (2012) has recently reported a unique feature of EGCG to stimulate
Fxr selectively in the mouse intestine and thus increase expression of its target gene Fgf15.
Actually, this mechanism has been suggested to protect the liver against cholestasis as it
may significantly reduce bile acid synthesis via Fgf15-mediated Cyp7a1 downregulation in
the liver (Modica et al., 2012). The opposite effect of EGCG on human CYP7A1
expression was described in human hepatoma (HepG2) cells, where EGCG (5µM) induced
CYP7A1mRNA levels by 4-fold (Lee et al., 2008). The authors also showed a direct
stimulatory effect of EGCG on human CYP7A1 promoter activity.
In contrast to the hepatoprotective activity, liver toxicity of green tea or EGCG
dietary supplements has been reported in humans. Liver injury in the affected individuals
ranged from elevated liver transaminase levels to hepatitis and hepatocellular necrosis
(Mazzanti et al., 2009). Also several cases of cholestasis have been described in humans
after either administration of green tea/green tea extract with high doses of EGCG or
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coadministration of green tea with estrogens, which are potentially cholestatic agents
(Mazzanti et al., 2009). Cases of green tea-related hepatotoxicity have been
comprehensively reviewed elsewhere (Sarma et al., 2008; Stickel et al., 2011).
1.2.2. EGCG and cholesterol metabolism
Positive effect of EGCG on cholesterol metabolism has recently attracted a considerable
interest. Epidemiologic studies were the first to draw attention to the hypocholesterolemic
activity of green tea when they showed a negative correlation between plasma cholesterol
levels and green tea consumption (Kono et al., 1992; Stensvold et al., 1992; Kono et al.,
1996;  Tokunaga  et  al.,  2002).  Later,  several  clinical  trials  came  to  the  same  conclusion.
A recent meta-analysis of 14 randomized controlled trials showed that green tea or its
extract significantly decreases plasma total cholesterol and low density lipoprotein (LDL)
cholesterol (Zheng et al., 2011). Several animal studies reported that green tea or its extract
reduced plasma cholesterol (Murase et al., 2002; Hasegawa et al., 2003; Kobayashi et al.,
2005; Bursill et al., 2007; Bursill and Roach, 2007) and liver cholesterol accumulation
(Muramatsu et al., 1986; Yang and Koo, 1997; Alshatwi et al., 2011) during high fat or
high cholesterol diet.
Pure EGCG also proved its ability to attenuate a diet-induced hypercholesterolemia
and  cholesterol  accumulation  in  the  liver  (Raederstorff  et  al.,  2003).  EGCG  has  been
shown  to  interfere  with  micellar  solubilization  of  cholesterol  in  the  intestine  and  thus  to
decrease cholesterol intestinal absorption (Ikeda et al., 1992). Later studies confirmed
increased cholesterol fecal excretion in EGCG-treated animals (Raederstorff et al., 2003;
Wang et al., 2006). Therefore, it is generally accepted that EGCG exerts its
hypocholesterolemic activity through reduced intestinal absorption of cholesterol and its
enhanced fecal excretion (Koo and Noh, 2007).
On the other hand, it is quite likely that EGCG exercises its effect on cholesterol
metabolism also at another level distinct from intestinal absorption. A growing body of in
vitro evidence suggests that EGCG may also affect cholesterol metabolism directly in the
liver. DNA microarray analysis showed that EGCG treatment altered expression of many
genes related to cholesterol metabolism in HepG2 cells (Goto et al., 2011). The most
pronounce  effect  was  the  upregulation  of  LDL  receptor.  Another  study  demonstrated  an
increased LDL receptor binding activity and protein mass in HepG2 cells treated with
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EGCG (Bursill and Roach, 2006). EGCG was also shown as a potent in vitro inhibitor of
squalene epoxidase (Abe et al., 2000) and 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG-CoA) reductase (Cuccioloni et al., 2011), two important enzymes in the cholesterol
biosynthetic pathway. Three reports showed that hepatocytes incubated in the presence of
EGCG secreted less apolipoprotein B-100 into the medium (Yee et al., 2002; Li et al.,
2006; Goto et al., 2011).
1.2.3. Pharmacokinetics of EGCG
Pharmacokinetic parameters in detail were studied in rats (Chen et al., 1997; Lin et al.,
2007). After oral administration, EGCG is absorbed in jejunum and ileum (Moore et al.,
2009), however, its bioavailability is rather low due to instability, low absorption and rapid
metabolism and excretion. Bioavailability of EGCG significantly varies with the species.
Only 2–5% of orally administered EGCG is absorbed systematically in rats, which is much
lower than the 26% bioavailability in mice (Lambert et al., 2003). First-pass effect of
EGCG (13% in rats) likely does not contribute significantly to the generally low
bioavailability of the compound (Lee et al., 1995). After intravenous administration,
distribution kinetics follows a two-compartment model. EGCG highly binds to plasma
proteins (~93%). When EGCG (10 mg/kg) was administered intravenously to rats,
biological half-life of the substance was 135 min, clearance and distribution volume were
72.5 mL/min/kg and 22.5 dL/kg, respectively. The highest tissue concentrations were
detected in the intestine and kidneys, lower levels were found in the liver and lungs (Chen
et al., 1997). EGCG is metabolized in the liver and intestine while undergoing methylation
and conjugation with glucuronide and sulfate (Lambert et al., 2003). Besides
bioavailability, metabolism of EGCG also differs among the species. Isolated rat liver
cytosol  has  been  shown  to  metabolize  EGCG  by  methylation  and  sulfation  more  readily
than human and mouse liver cytosol. The opposite is true for conjugation with glucuronide
(Lambert et al., 2003). In addition, EGCG is further metabolized by intestinal microflora
(Lambert et al., 2007). EGCG is probably excreted exclusively in bile as several studies
have not detected its presence in urine (Lee et al., 1995; Chow et al., 2001; Van
Amelsvoort et al., 2001; Lee et al., 2002).
Several studies evaluated EGCG kinetics also in humans. After drinking green tea
infusion,  plasma  concentrations  of  EGCG  remain  generally  below  0.5  µM.   Intake  of
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EGCG-rich dietary supplements resulted in peak plasma levels of 5-7 µM (Yang et al.,
2009). Bioavailability of EGCG in humans has not yet been studied due to the lack of an
intravenous formulation.
It has been shown that peak plasma concentrations of EGCG increase after repeated
administration in humans (Chow et al., 2003). Similarly, peak plasma concentrations of
EGCG were approximately five times higher in fasting condition than when administered
with food. Intake of EGCG supplements on empty stomach has been also associated with
a higher incidence of adverse effects (Chow et al., 2005).
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2. Aim of the study
The overall  objective  of  the  present  Ph.D.  thesis  was  to  explore  effect  of  EGCG on bile
production in rats under both normal conditions and pathological conditions of
ethinylestradiol-induced intrahepatic cholestasis.
The specific aims of the study were:
· To investigate effect of EGCG on bile formation and bile acid homeostasis
· To evaluate effect of EGCG on hepatic cholesterol excretion and metabolism
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3. Materials and methods
EGCG and ethinylestradiol were purchased from Cayman Chemical and Sigma-Aldrich,
respectively. Rhamnose and melibiose were purchased from Sigma. All other reagents and
supplies were obtained as specified in the text.
3.1. Animals and experimental design
All  animal  experimental  protocols  were  approved  by  the  Animal  Research  Committee  of
the Faculty of Medicine in Hradec Kralove, Charles University in Prague. Female Wistar
rats (230–250 g) were obtained from Anlab (Prague, Czech Republic). Animals were
housed under controlled temperature and light conditions, on a natural 12h light–dark cycle
and had free access to water and food throughout the experiments, but were fasted
overnight before sacrifice.
Experiment 1
Rats were randomly divided into four groups, namely:
1. Control rats (Ctrl), receiving propylene glycol (vehicle of ethinylestradiol) s.c.
for 5 consecutive days and saline (vehicle of EGCG) i.p. for 8 days;
2. EGCG-treated rats, receiving daily propylene glycol s.c. for 5 consecutive days
and EGCG (50 mg/kg bw) i.p. for 8 days;
3. Ethinylestradiol-treated rats (EE), which were administered daily with
ethinylestradiol (5 mg/kg bw) s.c. for 5 days and saline i.p. for 8 days;
4. EE-EGCG rats, which were coadministered with ethinylestradiol (5 mg/kg bw)
s.c. for 5 days and EGCG (50 mg/kg bw) i.p. for 8 days.
Administration of ethinylestradiol (or its vehicle propylene glycol) was started on day 4 of
EGCG (or saline) treatment, as illustrated in Figure 9. Bile collection, kinetic study of
rhamnose and melibiose and sacrifice were carried out on day 9, i.e. a day after the last
EGCG or ethinylestradiol dose.
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Figure 9. Schematic presentation of the study design. Control rats (Ctrl) received propylene glycol s.c. for 5
consecutive days and saline i.p. for 8 consecutive days. EGCG group received EGCG (50 mg/kg bw) i.p. for
8 days and propylene glycol s.c. injection for 5 consecutive days starting on day 4 of EGCG treatment. EE
group received i.p. injections of saline daily for 8 days and EE s.c. injections for 5 consecutive days starting
on day 4 of saline treatment. EE-EGCG group received EGCG (50 mg/kg bw) i.p. for 8 days and EE s.c. for
5 consecutive days starting on day 4 of EGCG administration.
If we extrapolate data from Kao et al. (2000), the dose of 50 mg/kg EGCG i.p. to
rats  may  result  in  plasma  concentrations  of  1  μM  after  1  hour  and  peak  plasma
concentrations  of  2  μM  after  2  hours.  The  plasma  concentration  of  1  μM  is  a  similar
concentration achievable in humans after either drinking ~8 cups of green tea or ingestion
of EGCG-rich extracts (Yang et al., 2009). The intraperitoneal route of the administration
may, by bypassing the intestine, secure a direct effect of EGCG on the liver. Moreover, it
may compensate for the low and variable bioavailability of EGCG in rats (Lambert et al.,
2003).
The bile collection and kinetic study of melibiose and rhamnose was performed on
day  9  of  the  experiment.  Rats  were  introduced  to  general  anesthesia  by  a  single  i.p.
injection of sodium pentobarbital (50mg/kg bw). The body temperature of rats was
maintained at 37°C by placement of the animals on a heating platform. The abdominal
cavity was opened and the common bile duct was exposed and cannulated. Thereafter, the
right jugular vein was cannulated for melibiose/rhamnose administration and for the
continuous infusion of normal saline (2 mL/h) to ensure hydration and to compensate for
blood loss due to blood sampling. For blood sampling the left carotid artery was
cannulated. After surgical preparations, rats received a single bolus dose of melibiose and
rhamnose (100 mg/kg bw). Blood samples (~0.3 mL) were taken at designated time
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intervals (–5, 4, 10, 30, 60, 90, 120, 180, and 240 min) after injection of the sugars. Plasma
samples were obtained from the whole blood by centrifugation at 5000 × g for 5 min at
4°C. Bile was collected in pre-weighed tubes at 30-min intervals. At the end of the kinetic
study, animals were sacrificed by exsanguination and livers were harvested, weighed, snap
frozen in liquid nitrogen and stored at –80°C until use. Bile flow was determined
gravimetrically without correction for relative density, assuming a bile density of 1.0 g/mL.
Experiment 2
Experiment 2, which had the same design of the drug administration as
Experiment  1,  was  performed  to  harvest  tissue  from  the  small  intestine.  Moreover,  feces
were collected from two cages in each group (2–3 animals per cage) during the last three
days of the treatment.
3.2. Liver histology
Right lobe of the excised liver was fixed in 10% neutral buffered formalin. Paraffin-
embedded liver tissue sections were prepared and stained with hematoxylin-eosin at the
Department of Histology and Embryology, Faculty of Medicine in Hradec Kralove.
Pictures were taken using Olympus BX51 microscope with Olympus DP71 camera.
3.3. Routine plasma biochemistry and 7α-hydroxy-4-cholesten-3-one
measurements
Plasma bilirubin concentrations and liver enzyme activities were determined by routine
laboratory methods on Cobas Integra 800 (Roche Diagnostics). Plasma triglycerides, total
cholesterol, high density lipoprotein (HDL) cholesterol, and LDL cholesterol were
determined by routine laboratory methods on a Hitachi automatic analyzer. Since HDL and
LDL cholesterol were measured, we could calculate concentrations of very low density
lipoprotein (VLDL) cholesterol by subtracting HDL and LDL cholesterol from total
cholesterol (Sanchez-Muniz and Bastida, 2008). Plasma concentrations of C4 were
measured by high-performance liquid chromatography (HPLC) at the Institute of Medical
Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine of Charles University,
as previously described (Lenicek et al., 2008). The chromatographic parameters were:
Tessek SGX C18 column (4 × 250 mm, 4 µm), acetonitrile:water (95:5, vol/vol) mobile
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phase, flow rate 1 mL/min, detection/reference wavelength 241/360 nm.
3.4. Evaluation of paracellular permeability
Hepatic tight junctional permeability (function of blood-biliary barrier) was assessed by
a dual sugar permeability test. As mentioned above, on day 9 of the experiment rats under
general anesthesia were injected with a single intravenous dose of melibiose and rhamnose
(100 mg/kg) at the beginning of bile collection and 4-h pharmacokinetic study was
performed. Plasma and biliary concentrations of melibiose and rhamnose were determined
by HPLC method with a fluorescent detection as previously described (Tomsik et al.,
2008). The ratio of biliary excretion of melibiose (disaccharide, which penetrates
selectively across the paracellular junctions) to biliary excretion of rhamnose
(monosaccharide, which permeates barriers by transcellular diffusion) was used as
a marker of liver paracellular permeability.
Despite the fact that the biliary excretion of these sugars is minor compared to
urinary excretion, the changes in biliary excretion of these sugars correlate very tightly
with the function of blood-biliary barrier (Tomsik et al., 2008).
3.5. Bile acid measurements
Bile acids in plasma, bile, liver tissue and feces were assayed using a commercial kit (Total
Bile Acids, Diazyme) and microplate reader Infinite 200 PRO (Tecan). While plasma
samples were assayed directly, bile samples were diluted 1:300 before the measurement.
Bile acids from liver tissue were extracted in 75% ethanol overnight and then heated up to
60°C for 2.5 h. After centrifugation (1500 × g, 10 min), the supernatant was assayed for
bile acids. Fecal samples from the last day of drug administration were weighted and air-
dried over 72-h period. Then 0.5 g of dried feces was minced and extracted in 10 mL of
75% ethanol at about 50°C for 2 h. The extract was centrifuged and total bile acids were
measured in the supernatant. The daily feces output (g/day per 100 g of bw) and fecal bile
acid  content  (µmol/g)  were  used  to  calculate  the  rate  of  bile  acid  excretion
(µmol/day/100 g of bw).
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3.6. Cholesterol, phospholipid and triglyceride measurements
Biliary concentrations of cholesterol and phospholipids were assessed by commercially
available kits Cholesterol Liquid 500 (Pliva-Lachema Diagnostika) and
Phosphatidylcholine Assay Kit (Cayman Chemical), respectively. Liver cholesterol and
triglyceride concentrations were determined by commercial kits Cholesterol Assay Kit
(Cayman Chemical) and Triglycerides 250 S (Pliva-Lachema Diagnostika), respectively,
after  extraction  of  hepatic  lipids  with  chloroform-methanol  2:1  according  to  Lee  et  al.
(2004). Hepatic esterified cholesterol concentrations were calculated by subtracting free
cholesterol from total cholesterol.
3.7. Glutathione measurements
Concentrations of reduced (GSH) and oxidized (GSSG) glutathione in bile and liver tissue
were analyzed separately using HPLC method (Kand'ar et al., 2007) on a Shimadzu system
with fluorescence detection. The chromatographic conditions employed in the study were
as follows: stationary phase SUPELCO Discovery C18 (4 mm × 150 mm, 5 mm), mobile
phase methanol:phosphate buffer (15:85, vol/vol, 25 mM, pH 6.0), flow rate 0.5 mL/min,
detector set at 350 nm and 450 nm (excitation and emission wavelengths, respectively).
Total glutathione was calculated as the sum of reduced glutathione and oxidized
glutathione (GSH + 2GSSG).
3.8. Lithogenic index
Lithogenic index was calculated according to the method of Thomas and Hofmann (1973)
and represents cholesterol saturation in the sample. The lithogenic index is defined as
a ratio of the actual molar percentage of cholesterol in the bile sample to the molar
percentage of cholesterol that is theoretically soluble. The molar percentage of




3.9. Quantitative real-time reverse transcription polymerase chain
reaction (qRT-PCR)
Liver tissue samples were homogenized using MagNA Lyser instrument (Roche) and total
RNA was isolated with RNeasy Mini Kit (Qiagen). Total RNA from primary human
hepatocytes, HepG2 cells and primary rat hepatocytes was isolated using TRI Reagent
(Invitrogen or Sigma-Aldrich) and cleaned up with Qiagen kit (RNeasy MinElute Cleanup
Kit).  One  to  five  micrograms  of  RNA  were  then  converted  into  cDNA  using  a  High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was
examined by qRT-PCR on 7500 HT Fast Real-time PCR system (Applied Biosystems).
Each reaction was conducted with 30 ng of cDNA (total RNA equivalent) in duplicates or
triplicates. Thermal cycling profile was 95°C for 20 sec, 40 cycles: 95°C for 3 sec, 60°C
for 30 sec. TaqMan Fast Universal PCR Master Mix and pre-designed TaqMan Gene
Expression Assay kits (Table 1) were purchased from Applied Biosystems. HMG-CoA
reductase assay was purchased from Generi Biotech. The relative changes in gene
expression were analyzed using ∆∆Ct method. Data were normalized to glyceraldehyde
3-phosphate dehydrogenase expression.
Table 1. Pre-designed TaqMan Gene Expression Assay kits used in the study.
































Liver samples were homogenized in RIPA buffer using MagNA Lyser instrument (Roche).
Protein concentration was measured with the bicinchoninic acid assay (Thermo Pierce)
using serum bovine albumin (Sigma) as a standard. Membrane-enriched fraction was
prepared from cytosolic fraction after spinning at 100 000 × g for 1 h (Denk et al., 2004).
Isolated canalicular membrane fractions were prepared according to Ito et al. (2001). Liver
homogenates were incubated with sample buffer at room temperature for 30 min and
separated on a polyacrylamide gel. After the proteins were transferred to a polyvinylidene
fluoride membrane (Millipore), the membrane was blocked for 1 h at room temperature
with 5% nonfat dry milk in Tris-buffered saline containing 0.05% Tween 20. The
membrane was then incubated with primary antibodies (Table 2) for 1 h or longer, washed,
and incubated for 1 h with a peroxidase-conjugated secondary anti-mouse or anti-rabbit
antibody (GE Healthcare). After washing three times, the membranes were developed
using enhanced chemiluminescent reagent (Thermo Pierce) and subjected to
autoluminography. The immunoreactive bands on the exposed films were scanned with
a densitometer ScanMaker i900 (UMAX) and semiquantified using the QuantityOne
imaging software (Bio-Rad). Beta-actin immunoblots were used as loading controls.
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Table 2. Primary antibodies used in western blot analyses.
Protein Source, catalog number Dilution
Abca1 Novus, NB 100-2068 1:2000
Abcg5 Abcam, ab45279 1:1000
Acat2 Cayman, 100027 1:500
Bsep Abcam, ab71793 1:1000
Cyp7a1 Abcam, ab 65596 1:1000
HMG-CoA reductase Abcam, ab98018 1:1000
LDL receptor Cayman, 10007665 1:1000
Mdr2 Abcam, ab71792 1:500
Mrp2 Alexis, ALX-801-037 1:500
Mrp3 Sigma, M0318 1:500
Mrp4 Abcam, ab32550 1:200
Ntcp Santa Cruz, sc-98485 1:300
Oatp1a1 Millipore, AB3570P 1:5000
Oatp1a4 Millipore, AB3572P 1:3000
Sr-b1 Novus, NB 400-104 1:2000
Srebp2 Abcam, ab30682 1:1000
β-actin Sigma, A5316 1:5000
3.11. Gene reporter assay for human FXR
HepG2 cell line was purchased from the European Collection of Cell Cultures (Salisbury,
UK) and was passaged no more than 25 times. All cells were maintained at 37°C in
a humidified atmosphere containing 5% carbon dioxide. For transient transfection gene
reporter experiments, HepG2 cells were maintained in antibiotic-free Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 1% sodium
pyruvate, and 1% nonessential amino acids (all from Sigma-Aldrich). HepG2 cells were
cotransfected with the pGL5-luc luciferase reporter construct (150 ng/well in 48-well
plate), 100 ng/well of the expression plasmid pCMX-GAL4-FXR containing FXR ligand
binding domain (Adachi et al., 2005) and pRL-TK (30 ng/well) using Lipofectamine 2000
(Life Technologies). Following 24 h of stabilization, HepG2 cells were treated with EGCG
(5 µM and 20 µM), chenodeoxycholic acid (CDCA; 50 µM), and vehicle (DMSO; 0.1%
v/v) for 24 h. Cells were then lysed and analyzed for firefly luciferase activity normalized
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to enzyme activity of the Renilla luciferase (Dual-Luciferase Reporter Assay, Promega).
3.12. Rat hepatocyte isolation, culture and treatment
Male Wistar rats (250–280 g) were used as liver donors and primary rat hepatocytes were
isolated by collagenase perfusion (Kand'ar et al., 2007) at the Department of Physiology,
Faculty of Medicine in Hradec Kralove. Sprague Dawley rats (170–200 g) as liver donors
were obtained from Charles River (Wilmington, MA) and primary hepatocyte isolation
was performed in the Liver Center of Yale University. All cells were maintained at 37°C in
a humidified atmosphere containing 5% carbon dioxide. In both sets of experiments,
hepatocyte suspensions were added to the precoated dishes at a density of 1 × 106 cells per
35-mm dish.  Two hours  after  plating,  the  medium was  aspirated  and  cells  were  overlaid
with 70 µL of collagen solution in William’s E medium (1.5 mg/mL, pH 7.4). One hour
later, fresh supplemented William’s E medium was added. William’s E medium for Wistar
rat hepatocytes contained fetal bovine serum (6%), glutamine (2 mM), penicillin
(100 IU/mL), streptomycin (10 mg/mL), dexamethasone (0.1 µg/mL), insulin
(0.08 IU/mL) and glucagon (8 ng/mL). William’s E medium for Sprague Dawley rat
hepatocytes contained fetal bovine serum (5%), glutamine (2 mM), penicillin (100 IU/mL),
streptomycin (10 mg/mL), gentamicin (8 µg/mL), dexamethasone (0.1 µM) and insulin
(4 mg/L). After 24 h, the medium was removed and replaced with a fresh serum-free
William’s E medium containing either DMSO or EGCG at concentration of 1-20 µM for
24 h incubation. Thereafter, cells were collected in TRI Reagent or Trizol Reagent (Sigma-
Aldrich or Invitrogen) for gene expression analysis.
3.13. Primary human hepatocyte isolation, culture and treatment
Primary human hepatocytes were obtained from the Liver Tissue Procurement and
Distribution System of the National Institutes of Health (Dr. Stephen Strom, University of
Pittsburgh, Pittsburgh, PA). Human hepatocytes were maintained on collagen coated plates
overlaid with Matrigel (BD Biosciences). All cells were maintained at 37°C in
a humidified atmosphere containing 5% carbon dioxide. Culture medium (HMM medium,
Lonza) contained dexamethasone (0.1 μM), insulin (0.1 μM), penicillin G (100 U/mL),
streptomycin (100 µg/mL), and amphotericin B (0.25 µg/mL). Twenty-four hours after
Matrigel  overlay,  cells  were  treated  with  either  DMSO  or  EGCG  at  concentration  of
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0.2-5 µM for 24 h. Cells were harvested in Trizol Reagent (Invitrogen) for gene expression
analysis.
3.14. HepG2 cell culture and treatment
HepG2 cells were obtained from the American Type Culture Collection (Manassas, VA)
and were used within 20 passages. Cells were maintained in DMEM containing 10% fetal
bovine serum (Gibco) and penicillin/streptomycin (100 U/mL, 100 µg/mL). All cells were
maintained at 37°C in a humidified atmosphere containing 5% carbon dioxide. At 50% to
70% confluence, cells were treated with DMSO or EGCG at concentration of 1-20 µM for
24 h in serum-free medium. Afterwards, cells were harvested in Trizol reagent (Invitrogen)
for gene expression analysis.
3.15. Rat Cyp7a1 promoter activity
The effect of EGCG on rat Cyp7a1 promoter activity was assessed in a dual-luciferase
gene reporter assay from Promega. Rat Cyp7a1 promoter reporter construct
(pGL2-Cyp7a1) was provided from J. Y. L. Chiang (Northeastern Ohio University) and is
described in a previous report as p-416Luc (Crestani et al., 1995).  HEK293 cells were
obtained from the American Type Culture Collection (Manassas, VA) and were maintained
in DMEM containing 10% fetal bovine serum (Gibco) and penicillin/streptomycin
(100 U/mL, 100 µg/mL). When cells reached 80% confluence, the culture medium was
changed to OPTI-MEM and cells were cotransfected with pGL2-Cyp7a1 (300 ng),
pCMV-LXRα and pCMV-RXRα expression plasmids (both 75 ng) and 1.5 ng phRL-CMV
per each well. Transfection was performed in triplicates in 24-well plates using
Lipofectamin 2000 (Invitrogen). After 24 h, cells were treated with DMSO, EGCG
(1-20 µM) and 22-(R)-hydroxycholesterol (5 µM) for an additional 24 h in 0.5% charcoal-
stripped fetal bovine serum DMEM. Cell lysate was prepared with passive lysis buffer
(Promega) and luminescence was measured by a Synergy2 Microplate Reader (BioTek).
Firefly luciferase activity was normalized to Renilla luciferase activity to control for
transfection efficiency and cell numbers. Data (firefly/Renilla luciferase activity) are
expressed as fold increase over vehicle-treated cells.
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3.16. Human CYP7A1 promoter activity
A dual-luciferase gene reporter assay (Promega) was utilized to evaluate the effect of
EGCG on human CYP7A1 promoter activity. HepG2 cells were obtained from the
American Type Culture Collection (Manassas, VA) and were maintained in DMEM
containing 10% fetal bovine serum (Gibco) and penicillin/streptomycin (100 U/mL,
100 µg/mL). Human CYP7A1 promoter reporter construct (pGL3-CYP7A1) was a gift
from  J.  Y.  L.  Chiang  (Northeastern  Ohio  University).  For  transfection  experiments,
medium was changed to OPTI-MEM medium and cells were cotransfected with pGL3-
CYP7A1 (300 ng), pGL3 (200 ng) and 1.5 ng phRL-CMV in triplicates, using X-Treme
HP (Roche) for each well in 24-well plates. Twenty-four hours later, cells were treated
with  DMSO,  EGCG  (1-5  µM)  and  CDCA  (50  µM)  for  an  additional  24  h  in  DMEM
containing 0.5% charcoal-stripped fetal bovine serum. Passive lysis, luminescence reading
and normalizing the activity were performed as described in method 3.16.
3.17. Statistical analysis
All data are expressed as the mean ± standard deviation (SD). Time-course experiments
were analyzed using a two-way analysis of variance (ANOVA) followed by Bonferroni
test  for post-hoc analysis.  For two-group comparison, Student’s t-test  was employed. For
multiple-group comparison, data were analyzed by one-way ANOVA followed by
Newman-Keuls test. Pearson correlation coefficients (r) were calculated. Differences were
considered significant at P-value less than 0.05. All analyses were performed using





The body weight of all animals was monitored on daily basis throughout the experiment.
While EGCG treatment did not affect the body weight, administration of ethinylestradiol led
to a moderate body weight loss (Fig. 10).
Figure 10. Time course of body weight change (A) and body weight change at the end of experiment (B) as a
percentage of initial body weight. Data are expressed as means ± SD for 6-7 animals per group. Significantly
different from the control group: * P < 0.05, *** P < 0.001.
4.2. Liver weight
At the end of the kinetic study, rat livers were harvested and weighted. EGCG administration
alone had no effect on the liver weight (Fig. 11). On the other side, ethinylestradiol caused
a significant liver weight increase, which was blunted by EGCG coadministration.
Figure 11.  Liver  weight  (A)  and  liver  weight  to  body  weight  ratio  (B).  Data  represent  means  ±  SD  for  6-7
animals per group. Significantly different from the control group: ** P < 0.01, *** P < 0.001. Significantly
different from EE group: # P < 0.05.
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Figure 8B shows liver weight normalized to body weight. Since the body weight of
EE-EGCG  rats  was  slightly  lower  at  the  end  of  experiment  compared  to  EE  group,  the
difference in liver to body weight ratio between these two groups is no longer statistically
significant.
4.3. Liver histology
Formalin-fixed paraffin-embedded liver sections were stained with hematoxylin-eosin and
examined by light microscopy. Livers of all groups showed normal liver architecture and no
hepatocyte injury (Fig. 12). Ethinylestradiol-induced cholestasis is a form of bland cholestasis
that does not exhibit parenchymal damage (Lindor, 2008).
Figure 12. Photomicrographs of hematoxylin-eosin-stained sections of liver tissue from the control, EGCG, EE
and EE-EGCG group (original magnification ×10).
4.4. Plasma biochemistry
The  sole  EGCG  administration  to  rats  did  not  significantly  affect  most  of  the  plasma
biochemistry markers except for the concentrations of bile acids and VLDL cholesterol.
EGCG elevated plasma bile acids by 2-fold (P < 0.05) compared to controls (Table 3), but it
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did not further raise ethinylestradiol-elevated plasma bile acids in EE-EGCG group.
Ethinylestradiol treatment in rats raised plasma bile acids and bilirubin compared to
controls. Further, ethinylestradiol administration lowered plasma triglycerides, total
cholesterol and HDL cholesterol while increased VLDL cholesterol fraction. Ethinylestradiol
treatment  also  diminished  levels  of  LDL  cholesterol  under  the  limit  of  detection.  EGCG  in
combination with ethinylestradiol further reduced plasma total cholesterol (due to a decrease
in VLDL cholesterol fraction), with no change in plasma HDL cholesterol compared with
ethinylestradiol-only administration. EGCG also further lowered ethinylestradiol-reduced
plasma levels of triglycerides.
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Table 3. Plasma biochemistry
Ctrl EGCG EE EE-EGCG
Total bile acids (μM) 13.5 ± 5.5   27.2 ± 8.2*       39.3 ± 12.6***       41.4 ± 13.1***
Total bilirubin (μM)   2.9 ± 0.7   2.7 ± 0.8      6.4 ± 1.8**       8.6 ± 4.2***
ALT (μkat/L)   1.0 ± 0.5   1.0 ± 0.5   1.7 ± 0.4   0.7 ± 0.1
AST (μkat/L)   2.2 ± 1.2   2.1 ± 0.6   1.7 ± 0.4   1.4 ± 0.5
LDH (μkat/L)   3.2 ± 1.9   2.5 ± 0.5   2.6 ± 1.0   2.1 ± 0.7
Total protein (g/L) 40.2 ± 5.2 37.5 ± 2.2 39.4 ± 5.8 35.3 ± 1.7
Albumin (g/L) 28.6 ± 3.9 28.9 ± 1.4 27.0 ± 3.5 25.7 ± 1.9
Glucose (mM)   9.8 ± 1.2   8.8 ± 1.3 10.0 ± 3.0   8.0 ± 1.0
Plasma lipids
Triglycerides (mM)  0.69 ± 0.18   0.87 ± 0.23    0.39 ± 0.23*         0.21 ± 0.04***#
Total cholesterol (mM)  1.25 ± 0.27   1.11 ± 0.17       0.41 ± 0.14***          0.16 ± 0.11***##
HDL cholesterol (mM)  0.87 ± 0.19   0.83 ± 0.18       0.04 ± 0.02***       0.03 ± 0.02***
LDL cholesterol (mM)  0.11 ± 0.06   0.08 ± 0.04 NDa NDa
VLDL cholesterol (mM)  0.27 ± 0.08     0.20 ± 0.06*    0.40 ± 0.08*         0.15 ± 0.08*###
Values are means ± SD for 6-7 animals per group. ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate
dehydrogenase. Significantly different from the control group: * P < 0.05, ** P < 0.01, *** P < 0.001. Significantly different from EE group:
# P < 0.05, ## P < 0.01, ### P < 0.001.




Following cannulation of the common bile duct, bile was collected in 30-minute intervals and
bile flow rate and cumulative bile flow were calculated (Fig. 13). Interestingly, the average
bile flow rate in EGCG-treated rats was reduced by 23% compared to the control group
(9.1 ± 0.8 vs. 11.7 ± 0.7 µL/min, P < 0.05). Ethinylestradiol administration to rats diminished
bile flow by ~ 60% regardless of EGCG treatment (P < 0.001) as the effect of ethinylestradiol
prevailed over the effect of EGCG.
Figure 13. Bile flow expressed as a time course of the bile flow rate (A) and cumulative bile flow (B). Values
are means ± SD for 6-7 animals per group. Significantly different from the control group: * P < 0.05,
** P < 0.01, *** P < 0.001.
4.6. Function of blood-biliary barrier
Since the function of blood-biliary barrier significantly affects bile formation, this parameter
was assessed by a previously described permeability test (Tomsik et al., 2008), which is based
on intravenous administration of melibiose and rhamnose. Plasma and biliary concentrations
of both sugars were measured and the ratio of biliary excretion of melibiose to rhamnose was
calculated.
The mean plasma concentrations of melibiose and rhamnose did not differ
significantly between groups throughout the kinetic study (Fig. 14).
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Figure 14. Plasma concentrations of melibiose (A) and rhamnose (B), and ratio of plasma concentration of
melibiose to plasma concentration of rhamnose (C). Values are means ± SD for 6-7 animals per group.
Regarding the biliary excretion of melibiose and rhamnose, differences were observed
in early phases of the bile collection (Fig. 15). Biliary excretion of melibiose was increased in
the first two intervals in ethinylestradiol-treated rats. When expressed in cumulative fashion,




Figure 15. Biliary excretion of melibiose (A) and rhamnose (B) and cumulative biliary excretion of melibiose
(C) and rhamnose (D). BE, biliary excretion. Values are means ± SD for 6-7 animals per group. Significantly
different from the control group: ** P < 0.01, *** P < 0.001. Significantly different from EE-treated group: ## P
< 0.01, ### P < 0.001.
The  ratio  of  biliary  excretion  (or  cumulative  biliary  excretion)  of  melibiose  to
rhamnose is a key marker of blood-biliary barrier impairment. The ratio was markedly
increased in the groups receiving ethinylestradiol and ethinylestradiol plus EGCG (Fig. 16),
which could allow for a paracellular regurgitation of bile constituents into the blood.
Although ethinylestradiol administration is known to increase paracellular permeability in rat
liver (Rodriguez-Garay, 2003), this particular permeability test was utilized in
ethinylestradiol-treated rats for the first time.
Results
50
Figure 16. Ratio of melibiose biliary excretion to rhamnose biliary excretion (A) and ratio of melibiose
cumulative biliary excretion to rhamnose cumulative biliary excretion (B). BE, biliary excretion. Values are
means ± SD for 6-7 animals per group. Significantly different from the control group: *** P < 0.001.
4.7. Biliary excretion of bile acids, glutathione and lipids
Biliary concentrations of bile acids, glutathione, cholesterol and phospholipids were measured




Figure 17. Biliary concentrations of bile acids (A), glutathione (B), cholesterol (C), and phospholipids (D).
Values are means ± SD for 6-7 animals per group. Significantly different from the control group: ** P < 0.05,
** P < 0.01, *** P < 0.001.
EGCG  treatment  did  not  affect  biliary  output  of  bile  acids  compared  to  controls
(Fig. 18), but reduced biliary glutathione excretion by ~70% (P < 0.001). Interestingly, EGCG
markedly enhanced biliary excretion of cholesterol and phospholipids by 84% and 50%
(P < 0.001), respectively. Ethinylestradiol lowered bile acid excretion to 40% of the control
value (P < 0.001) and nearly abolished glutathione biliary output (0.4% of controls,
P < 0.001). EGCG coadministration to ethinylestradiol had no effect on these parameters
compared to ethinylestradiol-only administration.
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Figure 18. Biliary excretion of bile acids (A), glutathione (B), cholesterol (C), and phospholipids (D). BE,
biliary excretion. Values are means ± SD for 6-7 animals per group. Significantly different from the control
group: *** P < 0.001.
Biliary bile acid excretion was evaluated in three different time points. Since the bile
drainage due to bile duct cannulation interrupted enterohepatic circulation of bile acids, the
early bile collection interval may best reflect the situation in the animals (Fig. 19).
Figure 19. Biliary excretion of bile acids over the time periods. BE, biliary excretion. Values are means ± SD for




Lithogenic index for each animal was calculated. Both EGCG and ethinylestradiol (or their
combination) significantly increased formation of lithogenic bile compared to controls
(Fig. 20).
Figure 20. Lithogenic index. Values are means ± SD for 6-7 animals per group. Significantly different from the
control group: * P < 0.05, ** P < 0.01.
4.9. Fecal bile acid excretion
EGCG-treated rats had a higher concentration of bile acids in feces (Fig. 21A) than the
control rats. The fecal bile acid excretion tended to be increased after EGCG treatment,
although this was not statistically significant (Fig. 21B). Bile acid content and fecal excretion
were significantly lower in ethinylestradiol-treated rats compared to controls.
Figure 21. Concentration of total bile acids in the feces (A) and fecal bile acid excretion (B). Values are means
± SD for 4 samples per group. Significantly different from the control group: * P < 0.05, ** P < 0.01.
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4.10. Liver bile acid concentration
Bile acid concentrations were measured in liver tissue. The mean hepatic bile acid
concentrations remained unaffected by EGCG treatment (Fig. 22). Ethinylestradiol is known
not to change hepatic bile acid levels (Davis and Kern, 1976).
Figure 22. Hepatic concentrations of bile acids. Values are means ± SD for 6-7 animals per group.
4.11. Liver glutathione concentration
Both reduced and oxidized forms of glutathione were measured in liver tissue. EGCG-treated
rats showed increased concentrations of oxidized glutathione, but unchanged levels of the
reduced form and total glutathione compared to controls (Fig. 23A-C). This, however, made
the GSH/GSSG ratio decrease significantly (Fig. 23D). Ethinylestradiol, on the other side,
markedly raised levels of reduced glutathione and thus levels of the total glutathione since the
reduced form is much more abundant than the oxidized form.
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Figure 23. Liver concentrations of reduced glutathione (GSH; A), oxidized glutathione (GSSG; B), total
glutathione (C) and ratio of reduced glutathione to oxidized glutathione (D).  Values are means ± SD for 6-7
animals per group. Significantly different from the control group: ** P < 0.01, *** P < 0.001. Significantly
different from EE-treated group: ##  P < 0.01, ###  P < 0.001.
4.12. Liver concentrations of lipids
A moderate decline in liver triglycerides was observed in EGCG-treated rats, whereas no such
change occurred when EGCG was coadministered with ethinylestradiol (Fig. 24A). EGCG
treatment alone affected neither free nor esterified cholesterol concentrations. On the contrary,
ethinylestradiol treatment substantially increased liver cholesterol content, inducing hepatic
cholesterol levels by ~50% compared to controls (P < 0.001) (Fig. 24B, D). This increase in
hepatic total cholesterol is attributable to the increment in esterified cholesterol. When
coadministered with ethinylestradiol, EGCG partially prevented ethinylestradiol-induced
cholesterol accumulation and liver weight increase by lowering hepatic esterified cholesterol
concentrations. In addition, cholesterol content per liver was tightly correlated with liver
weight (r = 0.89, P < 0.0001) and with both gene and protein expression of acyl-
coenzyme A:cholesterol acyltransferase (Acat2) (r =  0.82  and r = 0.71, respectively,
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P < 0.001), the principal enzyme responsible for cholesterol esterification.
Figure 24. Liver concentrations of triglycerides (A), total cholesterol (B), free cholesterol (C) and esterified
cholesterol (D). Values are means ± SD for 6-7 animals per group. Significantly different from the control group:
** P < 0.01, *** P < 0.001. Significantly different from EE-treated group: #  P < 0.05, ##  P < 0.01.
4.13. Expression of molecules involved in bile acid homeostasis
To evaluate effect of EGCG at the molecular level, gene and protein expression profiles of the
major hepatic bile acid transporters in the liver and intestine were examined by qRT-PCR and
Western  blotting.  EGCG  administration  decreased  mRNA  levels  of  two  major  bile  acid
transporters at the canalicular (Bsep) and basolateral (Ntcp) membrane by 34% and 24%
(P < 0.01 and P < 0.05), respectively (Fig. 25A). Nevertheless, their protein expression was
not changed compared to controls (Fig. 25B). On the other hand, EGCG nearly doubled
protein expression of Mrp4 (P < 0.001).
Similarly to previous reports (Geier et al., 2003; Fiorucci et al., 2005), ethinylestradiol
significantly reduced gene expression of Ntcp and Oatp1a4 and strongly upregulated Mrp3
(Fig. 25A). In ethinylestradiol-treated group, protein expression of Bsep, Ntcp, Oatp1a1,
Oatp1a4, Mrp2 was reduced, whereas Mrp4 protein mass was increased (Fig. 25B). EGCG
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coadministration to ethinylestradiol did not markedly alter gene or protein expression, except
for the increase in Oatp1a4 mRNA and Mrp4 protein.
Figure 25. Hepatic expression of bile acid transporters at the mRNA (A) and protein levels (B). Representative
immunoblots are shown (C). Bsep, bile salt export pump; Ntcp, Na+-taurocholate co-transporting polypeptide;
Oatp, organic anion transporting polypeptide; Mrp, multidrug resistance-associated protein. Values are means
± SD for 6-7 animals per group. Significantly different from the control group: * P < 0.05, ** P < 0.01,
*** P < 0.001. Significantly different from EE-treated group: #  P < 0.05.
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Gene expression of bile acid transporters was also evaluated in the ileum. All
experimental groups showed reduced expression of the main ileal bile acid transporters, Asbt
and  Ostα,  compared  to  controls  (Fig.  26).  On  the  contrary,  EGCG  administered  to
ethinylestradiol-treated rats increased mRNA levels of Asbt, Ostα and Ostβ compared to rats
administered with ethinylestradiol only.
Figure 26. Gene expression of the major bile acid transporters in the ileum. Values are means ± SD for 6-7 rats
per group. Asbt, apical sodium-dependent bile acid transporter; Ost, organic solute transporter. Significantly
different from the control group: * P < 0.05, ** P < 0.01. Signifi-cantly different from EE group: # P < 0.05,
## P < 0.01.
Next,  the  key  regulators  of  bile  acid  homeostasis  in  the  liver  and  intestine  were
evaluated at mRNA level. Fxr is the chief sensor of intracellular levels of bile acids,
controlling their synthesis and transport. Its gene expression in the liver was not significantly
altered by the treatment (Fig. 27). In all experimental groups, the expression of the orphan
nuclear receptor Shp was markedly upregulated in the liver, but reduced in the ileum.
Similarly, gene expression of Fgf15 in the ileum was significantly downregulated.
Figure 27. Gene expression of the major regulators of bile acid homeostasis in the liver and ileum. Values are
means ± SD for 6-7 rats per group. Fxr, farnesoid X receptor; Shp, small heterodimer partner; Fgf15, fibroblast
growth factor 15. Significantly different from the control group: * P < 0.05, ** P < 0.01, *** P < 0.001.
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4.14. Expression of Mrp2
Since biliary glutathione excretion was significantly impaired in all treatment groups, hepatic
expression of Mrp2, the key glutathione transporter,  was explored. Surprisingly,  none of the
treatments affected mRNA levels of Mrp2 in the livers (Fig. 28A).
Figure 28. Hepatic expression of Mrp2 at the mRNA (A) and protein levels (B-D). Mrp2 protein was detected in
the whole cell lysate (B), membrane-enriched fraction (C) and isolated canalicular membrane fraction (D). Mrp,
multidrug resistance-associated protein. Values are means ± SD for 6-7 animals per group. Significantly
different from the control group: ** P < 0.01, *** P < 0.001.
Mrp2 protein content was then examined in the whole cell lysate, which showed that
EGCG treatment reduced protein mass of Mrp by ~25% (p < 0.01, Fig. 28B) compared to
controls. Mrp2 protein content was then assessed in membrane-enriched fraction and isolated
canalicular  membrane  fraction  to  see  whether  endocytic  retrieval  or  redistribution  from  the
canalicular membrane plays a role in Mrp2 decreased function. Mrp2 protein contents in both
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membrane-enriched fraction and isolated canalicular membrane fraction were decreased to
a similar extent (Fig. 28C, D) as the total amount of protein ruling out involvement of
endocytic retrieval or redistribution. Protein expression of Mrp2 very tightly correlated with
both biliary glutathione excretion (r = 0.80, P < 0.0001) and bile flow rate (r = 0.86,
P < 0.0001).
4.15. Expression of molecules involved in cholesterol metabolism
Expression of a variety of enzymes, receptors and transporters involved in liver cholesterol
synthesis, uptake, esterification and secretion was evaluated at both mRNA and protein levels.
Compared to controls, EGCG treatment did not changed LDL receptor mRNA but
downregulated gene expression of Sr-b1 (which mediates selective uptake of HDL
cholesterol) and Abca1 (ATP-binding cassette transporter sub-family A member1, the main
cholesterol basolateral efflux transporter) by 30% (P < 0.001) and 60% (P < 0.01),
respectively (Fig. 29A). While EGCG did not alter Acat2 gene expression significantly, it
increased HMG-CoA reductase mRNA by 60% (P < 0.01). Most strikingly, EGCG-treated
rats exhibited a more than 5-fold increase in gene expression of Abcg5 and Abcg8
(P < 0.001), which function as a heterodimeric complex transporting cholesterol from the
hepatocytes into bile. Ethinylestradiol significantly reduced mRNA abundance of Sr-b1,
Abca1 and HMG-CoA reductase and markedly induced that of LDL receptor and Acat2
(Fig. 29A). Gene expression of the main biliary phospholipid transporter, Mdr2, did not differ
between the groups.
To confirm changes found in gene expression, levels of respective proteins were
assessed by Western blot. EGCG increased protein levels of Abcg5 and Sr-b1 by 77%
(P < 0.001) and 20% (P < 0.01), respectively, and decreased Acat2 protein by 70% (P < 0.01)
(Fig. 29B). Ethinylestradiol strongly induced LDL receptor protein mass, but no bands were
detected in the control group, as reported previously by Bertolotti and Spady (1996), even if
more protein from membrane-enriched fraction was used (data not shown). Ethinylestradiol-
treated rats had lower protein levels of Abcg5 (P < 0.01), HMG-CoA reductase and Sr-b1
(P < 0.001) compared to controls. On the other side, ethinylestradiol caused a significant
increase Acat2 protein (by ~2.5-fold, P < 0.001), which was blunted by EGCG




Figure 29. Hepatic expression of key regulators of cholesterol metabolism at the mRNA (A) and protein levels
(B). Representative immunoblots are shown (C). Abcg, ATP-binding cassette transporter sub-family G; Mdr2,
multidrug resistance protein2; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme-A; Acat2, acyl-
CoA:cholesterol acyltransferase 2; LDL, low density lipoprotein; Abca1, ATP-binding cassette transporter sub-
family A member 1; Sr-b1, scavenger receptor class B type 1. Values are means ± SD for 6-7 animals per group.
Significantly different from the control group: * P < 0.05, ** P < 0.01, *** P < 0.001. Significantly different
from ethinylestradiol-treated group: # P < 0.05.
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Expression of selected nuclear receptors and transcription factors (and their
downstream target genes) involved in cholesterol metabolism regulation was also assessed
(Table 4). While EGCG had no significant effect on their expression, ethinylestradiol
administration caused a marked induction of Shp and sterol regulatory element-binding
protein (Srebp) 1 mRNA and decrease in mRNA levels of sterol Srebp2 (P < 0.001). EGCG
supplementation in ethinylestradiol-treated rats normalized ethinylestradiol-induced gene
expression of Srebp1 and further increased Shp. In addition, ethinylestradiol plus EGCG
increased amount of the mature transcriptionally active form of Srebp2.
Table 4. Expression of selected genes and Srebp2 protein
Ctrl   EGCG      EE   EE-EGCG
Relative mRNA abundance
Lxrα 100 ± 31   65 ± 15    89 ± 19   117 ± 46
Srebp1 100 ± 38   77 ± 22 214 ± 53***   150 ± 45##
Srebp2 100 ± 19 102 ± 33   45 ± 9***     43 ± 5***
Fasn 100 ± 56   84 ± 37   55 ± 43     31 ± 12***
Nqo1 100 ± 39 105 ± 26 135 ± 79   134 ± 56
Shp 100 ± 91 291 ± 95 863 ± 350*** 1340 ± 529***#
Relative protein abundance
Srebp2 100 ± 26 186 ± 70 210 ± 69   284 ± 136**
Data are expressed as a percentage of the control value and represent means ± SD, n = 6–7. Protein levels of the
active, i.e. cleaved, form of Srebp2 were evaluated. Lxrα, liver X receptor; Srebp, sterol regulatory element-
binding protein; Fasn, fatty acid synthase; Nqo1, NAD(P)H dehydrogenase, quinone 1; Shp, small heterodimer
partner. Significantly different: *** P < 0.001,  **  P  <  0.01,  *  P  <  0.05  when compared to  the  control  group;
## P < 0.01, # P < 0.05 when compared to ethinylestradiol-treated group.
4.16. Gene reporter assay for human Fxr
Fusion expression construct with the ligand binding domains of human FXR fused to the
DNA binding domain of the transcription factor GAL4 was used to examine interaction of
EGCG and FXR. After 24-h treatment,  no effect  of EGCG on the activation of GAL4-FXR
construct was actually seen in HepG2 cells (Fig. 30). As  shown  previously  (Adachi  et  al.,




Figure 30. Interaction of EGCG and human FXR. Chenodeoxycholic acid (CDCA, 50 µM) was used as a
positive control in activating pGL5-luc reporter construct via the pCMX-GAL4-FXR. Data are shown as the
mean fold activation (normalized to the Renilla luciferase activity) relative to the vehicle treatment (DMSO).
Significantly different from vehicle treatment: * P < 0.05.
4.17. Effect of EGCG on bile acid synthesis in vivo
Cholesterol 7α-hydroxylase plays a key role in regulation of bile acid synthesis since it
catalyzes the first and rate-limiting step in the classic pathway of bile acid synthetic (Chiang,
2009). In EGCG-treated rats, hepatic expression of Cyp7a1 was increased by 5 and 1.5-fold at
mRNA  and  protein  levels,  respectively  (Fig.  31A,  B).  Bile  acid  synthesis  in  these  rats  was
also assessed by plasma levels of C4, which is a well described marker of Cyp7a1 activity.
The concentrations of C4 were actually doubled in EGCG-treated rats compared to controls
(Fig. 31C).
Figure 31. Effect of EGCG on bile acid synthesis in vivo. EGCG treatment in rats increased expression of
Cyp7a1 at both mRNA (A) and protein (B) levels and doubled plasma levels of C4 (C). Values are means ± SD
for 7 rats per group. C4, 7α-hydroxy-4-cholesten-3-one; Cyp7a1, cholesterol 7α-hydroxylase. Significantly
different from the control group: * P < 0.05.
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4.18. Effect of EGCG on bile acid synthesis in vitro
Since the EGCG-treated rats presented a 5-fold increase in Cyp7a1 mRNA levels, the direct
effect of EGCG on Cyp7a1 gene expression was evaluated in vitro. Two series of experiments
were conducted in primary rat hepatocytes cultured in a collagen-sandwich configuration and
isolated from either Wistar or Sprague Dawley rats. These experiments showed that EGCG at
10 µM and 20 µM concentrations significantly induced rat Cyp7a1 mRNA in vitro (Fig. 32).
Figure 32. Gene expression of Cyp7a1 in primary hepatocytes isolated from either Wistar rats (A) or Sprague
Dawley rats (B), cultured in a collagen-sandwich configuration and treated with EGCG (1–20 µM) for 24 h.
DCA and 6ECDCA were used as negative controls that downregulate Cyp7a1 mRNA expression. Cyp7a1,
cholesterol 7α-hydroxylase; DCA, deoxycholic acid; 6ECDCA, 6α-ethyl-chenodeoxycholic acid. Values are
means ± SD for 3 (A) and 6 (B) independent experiments. Significantly different from the vehicle treatment:
* P < 0.05, ** P < 0.01, *** P < 0.001.
Figure 33. Illustrative microphotograph of primary rat hepatocytes cultured in a collagen-sandwich
configuration (left) and primary human hepatocytes cultured in Matrigel matrix (taken with 40 × objective).
To address clinical relevance of the observed effect, EGCG effect on human CYP7A1
was tested in human primary hepatocytes and human hepatoma cell line. Surprisingly, the
EGCG treatment in human hepatocytes showed a reverse effect to the one observed in the rat
hepatocytes. In primary human hepatocytes, EGCG showed a tendency to decrease CYP7A1
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expression, although this was not statistically significant (Fig. 34A). EGCG treatment
(10-20 µM) in HepG2 cells resulted in a significant reduction in CYP7A1 mRNA, which was
mediated by neither SHP nor FGF19 as it was the case for CYP7A1 downregulation induced
by CDCA treatment (Fig. 34D-F).
Figure 34. Effect of EGCG on CYP7A1 gene expression was studied in primary human hepatocytes (A-C) and
HepG2 cells (D-F). atRA (1µM) and CDCA (50 µM) were used as negative controls for CYP7A1 mRNA
expression. CYP7A1, cholesterol 7α-hydroxylase; SHP, small heterodimer partner; FGF19, fibroblast growth
factor 19; atRA, all-trans retinoic acid; CDCA, chenodeoxycholic acid. Values are means ± SD for 3 (primary
human hepatocyte) and 6 (HepG2 cells) independent experiments. Significantly different from the vehicle-
treated cells: * P < 0.05, ** P < 0.01, *** P < 0.001.
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To assess whether EGCG affects Cyp7a1/CYP7A1 transcription directly, gene
reporter assay was performed using both rat and human promoter of Cyp7a1/CYP7A1. EGCG
had  no  effect  on  rat  Cyp7a1  promoter  activity,  no  matter  if  cells  were  transfected  with
reporter gene alone, cotransfected with the expression plasmid of HNF4α (not shown) or
LXRα (Fig. 35A). As expected, the natural LXRα ligand, 22-(R)-hydroxycholesterol,
increased  activity  of  rat  Cyp7a1  promoter.  EGCG  exerted  no  effect  on  human  CYP7A1
promoter either (Fig. 35B). CDCA (50µM) treatment was used as a negative control.
Figure 35. Effect of EGCG on rat Cyp7a1 promoter activity (A) and human CYP7A1 promoter activity (B) in
gene reporter assay. CDCA (50 µM) and 22OH-C (5 µM) were used as a negative and positive control for
human and rat promoter activity, respectively. hCyp7A1, human cholesterol 7α-hydroxylase; rCyp7a1, rat
cholesterol 7α-hydroxylase; CDCD, chenodeoxycholic acid; 22OH-C, 22-(R)-hydroxycholesterol. Values are




5.1. Effect of EGCG on bile formation and bile acid homeostasis
EGCG has been reported to have beneficial effects in various experimental models of liver
injury and diseases. On the other hand, a growing body of evidence has shown its toxic effect
on the liver. Although there is a great interest in how EGCG affects liver pathophysiology,
effect of EGCG on biliary physiology has not yet been studied. Thus, the present thesis
investigated effect of EGCG on bile flow and bile acid homeostasis in rats.
One of the major findings of the study is that EGCG has a cholestatic activity in rats as
its administration decreased both bile production and elevated plasma bile acids. Decreased
bile flow after EGCG treatment was likely a consequence of reduced Mrp2 protein
expression, which resulted in impaired biliary glutathione excretion (Fig. 18B). Hepatocyte
canalicular transporter Mrp2 mediates biliary excretion of glutathione and various organic
anions and their metabolites conjugated with glucuronate, glutathione or sulfate. Biliary
excretion of these compounds creates osmotic driving force in hepatic bile formation (BAIF).
In Mrp2 knockout mice, biliary glutathione excretion is nearly abolished (~6% of wild-type
mice) and bile flow is ~25% lower than in wild-type mice (Chu et al., 2006). Similarly,
compared to wild-type counterparts, Mrp2-mutant rats (TR- and EHBR rats) present
dramatically decreased biliary glutathione excretion together with a 50% decrease in bile flow
(Jemnitz et al., 2010). Since EGCG did not affect biliary bile acid excretion (BADF), the
observed decrease in bile flow in EGCG-treated rats is very likely a result of Mrp2 protein
reduction. The decreased biliary glutathione excretion confirmed decreased function of Mrp2.
These findings were also indirectly supported by a tight correlation between bile production,
glutathione excretion and Mrp2 protein expression. Direct inhibition of Mrp2 by EGCG may
be excluded as EGCG has been shown to lack inhibitory effect  on human MRP2 (Netsch et
al., 2005). Nevertheless, EGCG and its methyl metabolites were shown to be substrates for
MRP2 (Hong et al., 2003).
Since EGCG did not alter mRNA levels of Mrp2 in the liver, we can assume that the
EGCG effect on Mrp2 is based on posttranscriptional mechanisms. Posttranslational
regulation of plasma membrane transporters relates to the rate of protein synthesis, membrane
positioning, endocytic retrieval and degradation. Especially endocytic retrieval and
degradation seem to be relevant for Mrp2 regulation during cholestatic injury and drug
treatment (Trauner et al., 1997; Johnson and Klaassen, 2002; Zinchuk et al., 2005; Micuda et
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al., 2008). In the present study, EGCG likely did not alter Mrp2 membrane trafficking or
endocytic retrieval as the Mrp2 content in the isolated canalicular membrane fraction reflected
the overall content of the protein in whole cell lysate. Whether the decreased Mrp2 expression
by EGCG is due to modified translation or impaired protein turnover requires further
elucidation.
EGCG has recently been described as a unique modulator of mouse and human
Fxr/FXR, the key regulator of whole body bile acid homeostasis (Li et al., 2012). In this
report, EGCG moderately stimulated human FXR activity but, interestingly, inhibited FXR
transactivation in the presence of bile acids or other FXR agonists. In addition, when
administered to mice, EGCG induced transcription of Fxr target genes selectively only in the
intestine but not in the liver (Li et al., 2012).  In the present study, EGCG did not stimulate
Fxr target genes in the rat liver (Bsep gene expression was rather reduced). In the intestine of
EGCG-treated rats, contradictory to Li et al. (2012), Fxr target genes such as Shp and Ostα
were significantly downregulated, which perhaps suggests alteration of Fxr at the given
EGCG dose. Discrepancy between the described agonistic activity of EGCG on human FXR
reporter and the expression of Fxr target genes in our animals was the reason for reproducing
gene reporter experiments with human FXR. However, the activation of human FXR by
EGCG was not confirmed in our settings. What caused these discrepancies is not known. The
explanation might be a variable accumulation of endogenous coactivators (Li et al., 2012),
gene  reporter  assay  differences,  species  differences  (mouse  vs.  rat  vs.  human)  or  dose  and
duration of the treatment (two days in mice vs. eight days in rats).
An intriguing question is whether human and rat FXR/Fxr are regulated differentially.
Being aware of difficulties in interspecies interpretation, there is a significant concordance in
the spectrum of FXR substrates and FXR-regulated target genes (including similarity in
changes induced by cholestasis), which suggests a good probability that prediction the Fxr
function  is  unbiased.  Thus  based  on  these  data,  it  cannot  be  claimed that  EGCG is  an  FXR
agonist or that it acts in vivo rather like an antagonist. Relevant human data from clinical
studies are needed to explain the discrepancy.
Another particular novel finding in the present study is that EGCG-treated rats
presented elevated plasma bile acids, although the biliary bile acid excretion was not altered.
Such a situation might be caused by either altered enterohepatic circulation of bile acids or
increased bile acid biosynthesis (Li et al., 2010). At the level of the liver, enterohepatic
recycling of bile acids was not apparently altered by EGCG because the biliary bile acid
excretion was not changed. This was in agreement with unchanged protein expression of the
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main bile acid transporters (Bsep, Ntcp, and Oatps). In contrast, the main bile acid
transporters (Asbt, Ost) in the ileum were significantly downregulated. This may account for
the increased bile acid content in feces of EGCG-treated rats, which was also observed after
green tea administration (Yang and Koo, 2000). Decreased bile acid absorption is, however,
in contradiction to the elevated plasma bile acid levels.
Regarding bile acid biosynthesis, EGCG administration to rats significantly increased
mRNA and protein expression of Cyp7a1, the key and rate-limiting biosynthetic enzyme in
the liver. The increased activity of this enzyme was further documented by increased
concentrations  of  C4  in  plasma  of  EGCG-treated  rats.  To  confirm  the  EGCG-mediated
induction of Cyp7a1 and obtain information on effective EGCG concentration, effect of
EGCG was studied in vitro in primary rat hepatocyte. In vitro EGCG upregulated Cyp7a1
mRNA at concentrations above 10 µM. Gene reporter experiments, however, indicated that
EGCG itself does not increase rat Cyp7a1 promoter activity. In vivo,  a  distinct  mechanism
which may cause the induction of Cyp7a1 is downregulation of intestinal Fgf15, which, in
turn, is followed by disinhibition of Cyp7a1 expression in the liver (Chiang, 2009). Since the
extent of plasma bile acid increase corresponded to the extent of plasma increase of C4 in
EGCG-treated animals, the induction of Cyp7a1 is a likely cause of elevated plasma bile acids
by EGCG. Based on our data, the mechanism of EGCG-mediated changes in bile acid
turnover is summarized in Figure 36.
 Effect of EGCG on CYP7A1 was also investigated in human hepatocytes. In contrast
to  the  rat  homologue,  EGCG  rather  decreased  expression  of  the  human  CYP7A1  gene  and
had no effect on CYP7A1 promoter activity. This observation was in a direct contradiction to
a previously published report describing ability of EGCG to induce human CYP7A1 mRNA
in HepG2 cells through increased CYP7A1 promoter activity (Lee et al., 2008). The reason
for this discrepancy is unknown in spite of the fact that a number of experiments were
performed either exactly according to Lee et al. (2008) or with various modifications.
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Figure 36. Schematic representation of the proposed mechanism of the EGCG effect on bile acid homeostasis in
rats. EGCG-treated rats showed downregulation of the main bile acid transporters in the intestine, Asbt and Ostα.
Consequently decreased reabsorption of bile acids in the ileum was documented by increased bile acid content in
feces of EGCG-treated rats. On the other side, EGCG prevented transcription of Fgf15 within the enterocytes.
Given  that  Fgf15  is  to  be  transported  to  the  liver  to  regulate  basal  Cyp7a1  gene  expression  by  binding  to  its
receptor Fgfr4, the lost of Fgf15 signaling caused disinhibition of Cyp7a1 transcription in the liver. Increased
Cyp7a1 expression led to enhanced bile acid synthesis as evidenced by elevated plasma levels of C4. Since
biliary bile acid excretion remained unchanged in EGCG-treated rats, the enhanced bile acid synthesis is a likely
cause of raised plasma bile acids. Asbt, apical sodium-dependent transporter; BA, bile acid; Bsep, bile salt
export pump; C4, 7α-hydroxy-4-cholesten-3-one; Cyp7a1, cholesterol 7α-hydroxylase; Fgf, fibroblast growth
factor; Fgfr, fibroblast growth factor receptor; Fxr, farnesoid X receptor; Mrp, multidrug resistance-associated
protein; Ost, organic solute transporter; Rxr, retinoid X receptor.
In parallel, EGCG effect was studied in ethinylestradiol-treated rats. Ethinylestradiol
administration to rats is a well established model of intrahepatic cholestasis characteristic of
decreased both BADF and BAIF of bile flow. In ethinylestradiol-treated rats, the lower BAIF
has been attributed to a significant endocytic internalization of Mrp2 from the canalicular
membrane into an intracellular compartment and further to reduced Mrp2 protein expression
and reduced Mrp2 transport activity (Trauner et al., 1997; Mottino et al., 2002). BADF is
likely diminished by trans-inhibition of Bsep after secretion of estrogen metabolites into bile
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via Mrp2 (Stieger et al., 2000). Further, estrogens alter hepatocyte bile acid uptake by
decreasing  the  expression  of  basolateral  transporters  such  as  Ntcp  and  Oatps  (Simon  et  al.,
1996; Geier et al., 2003). Molecular changes detected in ethinylestradiol-treated animals in
this  study  fully  complied  with  the  current  concept  of  this  form  of  cholestasis  (Geier  et  al.,
2003; Fiorucci et al., 2005; Ruiz et al., 2007). Changes in the gene expression of bile acid
transporters detected are summarized in Figure 37. It is of note that downregulation of ileal
bile acid transporters in ethinylestradiol-treated rats has been described here for the first time
and may signify a new adaptive mechanism in this type of cholestasis.
Under conditions of ethinylestradiol-induced cholestasis, EGCG showed only
a tendency for further decrease in Mrp2 protein expression and biliary glutathione excretion,
which was not reflected by a reduction in bile flow.
Figure 37. Schematic representation of changes in bile acid transporter gene expression in ethinylestradiol-
treated rats. As an adaptive response to cholestasis, basolateral bile acid transporters are all downregulated to
prevent accumulation of bile acids within the hepatocytes. Alternative basolateral efflux pumps may by
upregulated to redirect bile acid elimination towards renal excretion. Expression of canalicular transporters Mrp2
and Bsep is not change at the mRNA level, but a variety of posttranscriptional mechanisms are involved in Mrp2
and Bsep decreased function. Downregulation of the main bile acid transporters in the ileum, Asbt and Ostα, was
newly observed in ethinylestradiol-treated rats. Asbt, apical sodium-dependent transporter; Bsep, bile salt export
pump; Mrp, multidrug resistance-associated protein; Ntcp, Na+-taurocholate cotransporting polypeptide; OATP,
organic anion transporting polypeptide; Ost, organic solute transporter.
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5.2. Effect of EGCG on cholesterol metabolism
The present study investigated effect of EGCG on biliary cholesterol excretion and
metabolism in the liver. The results showed that EGCG administration to rats significantly
enhanced biliary cholesterol and phospholipid excretion. In addition, EGCG coadministration
attenuated ethinylestradiol-induced liver cholesterol accumulation and liver weight increase.
Biliary excretion is a major route for eliminating cholesterol from the body (Dikkers
and Tietge, 2010). The biliary cholesterol excretion rate is determined by both biliary bile
acid secretion and activity of canalicular transporters ABCG5 and ABCG8. The importance
of the ABCG5/8 complex in biliary cholesterol secretion was demonstrated by extremely low
biliary cholesterol in Abcg5/8 knockout mice (Yu et al., 2002a). On the other hand,
overexpression of human ABCG5/8 in mice promoted biliary cholesterol secretion (Yu et al.,
2002b). In addition, it has been shown that expression of MDR2 is required for ABCG5/8-
mediated biliary cholesterol secretion (Langheim et al., 2005). This is consistent with the
former finding that biliary cholesterol excretion is dramatically decreased in Mdr2-deficient
mice (Oude Elferink et al., 1995). Finally, biliary cholesterol excretion can be regulated by
Sr-b1, which is a selective HDL cholesterol receptor (Wiersma et al., 2010). Since HDL
cholesterol is the preferred source of biliary cholesterol, Sr-b1 knockout mice have biliary
cholesterol excretion decreased nearly to 50% (Mardones et al., 2001).
In the present study, EGCG treatment doubled biliary cholesterol excretion in rats. In
line with this finding, the expression of the crucial transporters Abcg5/8 was significantly
increased by EGCG at both mRNA and protein levels. There was a modest increase in Sr-b1
protein too. Because biliary bile acid excretion remained unchanged in EGCG-treated rats, the
data suggest that the upregulation of Abcg5/8 mediated the enhanced biliary cholesterol
secretion in these rats.
Biliary cholesterol excretion may also be promoted by increased availability of free
cholesterol within hepatocytes. This increased availability of free cholesterol can result from
higher activity of HMG-CoA reductase, i.e., increase de novo cholesterol synthesis (Rigotti et
al., 1989; Hooiveld et al., 1999) or inhibition of Acat2, i.e., decreased cholesterol
esterification (Nervi et al., 1983; Nervi et al., 1984). In the present study, EGCG upregulated
HMG-R mRNA but the protein levels remained unaltered. Given the unchanged HMG-CoA
reductase protein, it can be speculated that increased cholesterol synthesis did not likely
contribute to the enhanced biliary cholesterol secretion by EGCG. In contrast, EGCG-
mediated induction of cholesterol biliary excretion strongly correlated with the decreased
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expression of Acat2. The reduced expression of Acat2 and consequently reduced cholesterol
esterification could transiently increase free cholesterol that is available for biliary secretion,
as was previously demonstrated for progesterone and diosgenin (Nervi et al., 1983; Nervi et
al., 1984). In accordance, EGCG treatment in rats decreased plasma levels of VLDL
cholesterol, the production of which is also mediated by Acat2 (Shelness and Sellers, 2001)
Since biliary cholesterol and VLDL cholesterol seem to have a common hepatic pool (Stone
and Evans, 1992), the increased biliary loss of free cholesterol may compensate for the
decreased VLDL production due to impaired Acat2 activity. As a result, the liver
concentrations  of  free  and  esterified  cholesterol  were  not  finally  affected  by  EGCG,  but
plasma VLDL cholesterol was significantly lowered in both groups receiving EGCG. In
agreement, previous in vitro studies have reported that EGCG inhibited secretion of the
essential VLDL protein, apolipoprotein B (Yee et al., 2002; Li et al., 2006; Goto et al., 2011).
EGCG-treated rats had a significantly higher biliary output of phospholipids compared
to controls. Surprisingly, expression of Mdr2, the major phospholipid transporter, was not
changed by EGCG. Thus, biliary phospholipid excretion may be coupled to the excretion of
cholesterol in EGCG-treated rats, similarly as the overexpression of ABCG5/8 increased
biliary phospholipids in mice (Yu et al., 2002b).
EGCG has exerted hypocholesterolemic effect in both preclinical and clinical settings
(Zheng et al., 2011). In the present study, however, EGCG decreased plasma cholesterol
significantly only in ethinylestradiol-treated animals, not in healthy rats. This is actually in
accordance with several previous reports that detected cholesterol-lowering action of EGCG
or green tea only when plasma cholesterol concentrations were altered by another treatment
(Miura et al., 2001; Kaviarasan et al., 2008; Devika and Stanely Mainzen Prince, 2009).
Ethinylestradiol  at  the  given  dose  is  well  known  to  cause  liver  cholesterol
accumulation in rats (Rodriguez-Garay, 2003). This effect is primary mediated by
substantially induced expression of LDL receptor and thus increased uptake of plasma LDL
by hepatocyte (Bertolotti and Spady, 1996). In addition, in ethinylestradiol-treated rats plasma
total cholesterol and triglycerides decline while newly secreted VLDL particles are enriched
with esterified cholesterol (Nervi et al., 1984). Green tea has been shown to prevent
cholesterol accumulation in the liver of rats on high-cholesterol diet (Muramatsu et al., 1986;
Yang and Koo, 1997; Alshatwi et al., 2011). Similarly, EGCG in the present study attenuated
liver cholesterol accumulation and liver weight increase induced by ethinylestradiol
treatment. This preventive effect may be ascribed to the reduced Acat2 expression and to the
consequent decrease in liver esterified cholesterol content and VLDL production. Reports on
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biliary cholesterol excretion in ethinylestradiol-treated rats differ; both no change (Davis and
Kern, 1976; Bonazzi et al., 1986) and decrease (Kamisako and Ogawa, 2003) in this
parameter have been reported. In the present study, cholesterol excretion into bile was not
altered by ethinylestradiol administration, although Abcg5 was significantly reduced.
Elucidation of this discrepancy requires further investigation.
The mRNA data suggest that EGCG has ability to regulate expression of a variety of
genes involved in cholesterol metabolism. However, what is the particular molecular
mechanism of EGCG action remains an open question at this moment. Expression of the
genes evaluated in the present study is regulated by several nuclear receptors and transcription
factors.  Among these,  LXRα,  SREBP1 and SREBP2 seem to play the key roles (Wagner et
al., 2011). However, information on EGCG interaction with nuclear receptors is scarce. The
ability of EGCG to modulate FXR activity is discussed above (Section 5.1.). EGCG has also
been shown to modulate activity of transcription factor Nrf2 (Na and Surh, 2008). In the
present study, an inverse pattern in the expression of key liver lipid regulators was observed
compared to Nrf2 knockout mice (Huang et al., 2010), including 3-fold increase in Shp,
a target gene of Nrf2. Nevertheless, the expression of Nqo1, another direct Nrf2 target, was
not increased in EGCG-treated rats, suggesting that Nrf2 downstream target genes were not
uniformly activated by EGCG. Kuhn et al. (2004) have shown that EGCG increases presence
of the active form of SREBP2 via inhibition of its degradation by the ubiquitin-proteasome
system in HepG2 cells. Similarly, in the present project, protein levels of Srebp2 active form
were doubled in EGCG-treated rats compared to controls. However, from the other two
known targets of Srebp2, only mRNA of HMG-CoA reductase was upregulated by EGCG,
but not mRNA of LDL receptor. Further, EGCG strongly induced mRNA levels of Abcg5 and
Abcg8, which are Lxrα target genes (Repa et al., 2002). Because other Lxrα targets, Abca1,
Srebp1 and its downstream fatty acid synthase (Fasn), were not affected by EGCG in this
study, it may be possible that Lrh-1 or Hnf4α contributed to Abcg5/8 upregulation (Freeman
et al., 2004; Sumi et al., 2007). Taken together, the present findings indicate that the effect of
EGCG on cholesterol metabolism is very complex and involves several regulatory pathways
with a cross-talk between nuclear receptors and transcription factors. The proposed




Figure 38. Schematic representation of the proposed mechanism of EGCG action on liver cholesterol
metabolism in rats. EGCG induced protein expression of Sr-b1, which mediates selective uptake of HDL
cholesterol, the main source of biliary cholesterol. On the contrary, EGCG decreased expression of Acat2, the
enzyme responsible for hepatic cholesterol esterification. It is proposed that the EGCG-decreased Acat2
expression and consequently reduced cholesterol esterification diminished VLDL production and made excess
free cholesterol available for biliary secretion. EGCG enhanced expression of the key biliary cholesterol
transporters, Abcg5 and Abcg8, which together with higher free cholesterol availability promoted cholesterol
excretion into bile. Although HMG-CoA reductase protein levels were not significantly changed by EGCG, both
conversion of Srebp2 into its active form and expression of Srebp2 target gene were induced in EGCG-treated
rats. Abcg, ATP-binding cassette transporter sub-family G; Acat2, acyl-coenzyme A:cholesterol
acyltransferase 2; HMG-R, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase; Sr-b1, scavenger receptor




6.1. Effect of EGCG on bile formation and bile acid homeostasis
The present study has demonstrated that EGCG in rats raises plasma bile acid
concentrations through Cyp7a1 upregulation and induces cholestasis by reduced Mrp2
protein expression and thus reduced biliary glutathione excretion.
While decreased intrabiliary pressure due to reduced bile formation may contribute
to positive effects of EGCG in obstructive cholestasis, a potential for development of
intrahepatic cholestasis by EGCG exists, which may caution against a long-term excessive
use of EGCG-rich dietary supplements.
6.2. Effect of EGCG on cholesterol metabolism
 This is the first study to show that EGCG supplementation significantly increases biliary
cholesterol and phospholipid excretion. In addition, EGCG coadministration attenuates
hepatic cholesterol accumulation and liver weight increase in ethinylestradiol-treated rats.
These effects are attributable to upregulation of cholesterol transporters Abcg5/8 and Sr-b1
and  to  decreased  expression  of  Acat2  by  EGCG.  The  data  provide  new  insights  into




Epigallocatechin gallate (EGCG), the major green tea catechin, has been shown to be
protective in various experimental models of liver injury. Since its effect on biliary
physiology and liver cholesterol homeostasis has not been thoroughly studied, the present
study investigated effect of EGCG on bile flow, bile acid homeostasis and cholesterol
metabolism in healthy and ethinylestradiol-treated rats. Compared to controls, EGCG
treatment in rats decreased bile flow by 23%. Hepatic paracellular permeability and biliary
bile acid excretion were not altered by EGCG administration, but biliary glutathione
excretion was reduced by 70%. Accordingly, the main glutathione transporter at the
hepatocyte canalicular membrane, multidrug resistance-associated protein 2 (Mrp2), was
significantly decreased at the protein level. Interestingly, EGCG markedly enhanced biliary
excretion of cholesterol and phospholipids. These changes tightly correlated with increased
expression of ATP-binding cassette transporter G5 and G8 (Abcg5/8) and scavenger
receptor  class  B  type  1  and  with  decreased  expression  of  acyl-CoA:cholesterol
acyltransferase (Acat2). EGCG administration to rats also doubled plasma bile acid
concentrations compared to controls. While protein expression of the main hepatic bile
acid transporters was unchanged, the rate-limiting enzyme in the bile acid synthesis,
Cyp7a1, was significantly increased by EGCG. Enhanced bile acid synthesis in these
animals was also confirmed by a 2-fold increase in plasma marker of Cyp7a1 activity,
7α-hydroxy-4-cholesten-3-one. In contrast, EGCG markedly downregulated the major bile
acid transporters (Asbt and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum.
When EGCG was coadministered with ethinylestradiol, a potent cholestatic agent,
it did not show any additional effect on the induced cholestasis but reduced plasma total
cholesterol and VLDL cholesterol. Further, EGCG coadministration in ethinylestradiol-
treated rats attenuated liver weight increase and liver cholesterol accumulation, which was
linked with the corresponding reduction in Acat2 expression.
This study showed ability of EGCG to raise plasma bile acid concentrations, mainly
through Cyp7a1 upregulation, and to decrease bile production through reduction in
Mrp2-mediated bile flow. Despite the cholestatic effect, EGCG enhanced biliary
cholesterol excretion and attenuated ethinylestradiol-induced liver cholesterol
accumulation through Abcg5/8 upregulation and Acat2 reduction, respectively.
Collectively, these data significantly contribute to the current knowledge of EGCG effect
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Epigallocatechin gallate (EGCG) has been shown to be protective in various experimental
models of liver injury, although opposite effects have also been reported. Since its effect
on biliary physiology has not been thoroughly investigated, the present study evaluated
effect  of  EGCG  on  bile  flow  and  bile  acid  homeostasis  in  rats.  Compared  to  controls,
EGCG treatment decreased bile flow by 23%. Hepatic paracellular permeability and biliary
bile  acid  excretion  were  not  altered  by  EGCG  administration,  but  biliary  glutathione
excretion was reduced by 70%. Accordingly, the main glutathione transporter on the
hepatocyte canalicular membrane, multidrug resistance-associated protein 2 (Mrp2), was
significantly decreased at the protein level. EGCG administration also doubled plasma bile
acid levels compared to controls. While protein levels of the main hepatic bile acid
transporters were unchanged, the rate-limiting enzyme in the bile acid synthesis, Cyp7a1,
was significantly increased by EGCG. Enhanced bile acid synthesis in these animals was
also confirmed by a 2-fold increase in plasma marker 7α-hydroxy-4-cholesten-3-one. In
contrast, EGCG markedly downregulated major bile acid transporters (Asbt and Ostα) and
regulatory molecules (Shp and Fgf15) in the ileum. When EGCG was coadministered with
ethinylestradiol, a potent cholestatic agent, it did not show any additional effect on the
induced cholestasis. This study shows ability of EGCG to raise plasma bile acid
concentrations, mainly through Cyp7a1 upregulation, and to decrease bile production
through reduction in Mrp2-mediated bile acid-independent bile flow. In conclusion, our
data demonstrate that under certain conditions EGCG may induce cholestasis.




Bile  production  is  one  of  the  essential  functions  of  the  liver  and  is  vital  for  both  proper
digestion of dietary lipids and elimination of lipid soluble endo- and xenobiotics, including
drugs  and  toxins.  The  key  step  in  the  whole  process  is  secretion  of  osmotically  active
compounds, especially bile acids and glutathione, across the hepatocyte canalicular
membrane into the bile capillaries, followed by passive movement of water (Esteller,
2008). To generate the driving force for bile flow, solutes are transported into bile against a
concentration gradient by energy-dependent transporters; bile salt exporting pump (Bsep)
is essential for bile acid-dependent bile flow and multidrug resistance-associated protein
(Mrp) 2 is crucial for bile acid-independent bile flow, which is based on the transport of
glutathione and glutathione conjugates. Nevertheless, since bile acids are synthesized from
cholesterol and the majority of their pool undergo excessive enterohepatic recirculation,
several other transporters and enzymes in the liver and intestine are also crucial for proper
functionality of the whole process (Esteller, 2008).
Epigallocatechin gallate (EGCG), the main active component of green tea, is
currently a widely used natural compound available in numerous products either in purified
form or as a part of tea or tea extracts. EGCG has demonstrated a great variety of health
benefits, which are mainly related to its potent anti-oxidant, anti-inflammatory and
anticancer activities (Singh et al., 2011). Among these, one of the prominent effects is its
hepatoprotective action in various forms of liver injury (Ramesh et al., 2009; Ren et al.,
2011; Tipoe et al., 2010), including cholestatic injury induced by bile duct ligation
(Kobayashi et al., 2010; Zhong et al., 2003). Although most of these effects are ascribed to
the anti-inflammatory activity of the compound, Li et al. (2012) has recently reported a
unique feature of EGCG to stimulate farnesoid X receptor (Fxr), the master regulator of
bile acid homeostasis, selectively in the intestine and thus increase expression of its target
gene fibroblast growth factor 15 (Fgf15, a mouse homologue of human FGF19). This
mechanism has been suggested to protect the liver against cholestasis as it may
significantly reduce bile acid synthesis in the liver (Modica et al., 2012). However, the
effect of EGCG on bile flow and corresponding mechanisms has not yet been thoroughly
studied. In contrast, our recent data showed a bile flow decreased in EGCG-exposed rats
(Hirsova et al., 2012). In fact, such information is of great interest since several cases of
cholestasis have been reported in humans after either administration of high dose of
EGCG/green  tea  or  coadministration  with  other  potentially  cholestatic  agents,  such  as
ethinylestradiol (Mazzanti et al., 2009), a widely used contraceptive. The mechanism
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involved may therefore account for possible toxic effects of EGCG reported recently (for
review see Stickel et al., 2011).
The  aim  of  the  present  study  was  to  identify  the  effect  of  EGCG  on  overall  bile
production as well as to analyze separate effects on bile acid-dependent and bile acid-
independent bile flow. In view of the current concept that FXR activators may be useful in
treating intrahepatic cholestasis due to suppression of bile acid synthesis and promotion of
bile acid efflux from hepatocytes (Zhu et al., 2011), the effect of EGCG in our study was
further analyzed in a model of intrahepatic cholestasis induced by ethinylestradiol (EE).
2. Materials and Methods
2.1. Materials
Epigallocatechin gallate and ethinylestradiol were obtained from Cayman Chemical and
Sigma-Aldrich, respectively. Rhamnose and melibiose were purchased from Sigma.
2.2. Animals and experimental design
All animal experimental protocols were approved by the Animal Research Committee of
the Faculty of Medicine in Hradec Kralove, Charles University in Prague, Czech Republic.
Female Wistar rats (230–250 g) were obtained from Anlab (Czech Republic) and were
housed under controlled temperature and light conditions, on a natural 12 h light–dark
cycle. Animals had free access to water and food throughout the experiment, but were
fasted overnight before sacrifice. Because the decrease in bile flow by EGCG was first
noticed in our previous study (Hirsova et al., 2012), we decided to use the same study
design. Briefly, rats were randomly divided into four groups and were administered either
EGCG 50 mg/kg body weight (EGCG group) or saline (control group, Ctrl) by i.p.
injection once daily for 8 consecutive days. Groups EE and EE-EGCG received also
ethinylestradiol (5 mg/kg body weight) s.c. once daily for 5 days, starting on day 4 of
saline  or  EGCG  treatment.  This  dose  of  EGCG  (50  mg/kg)  may  result  in  a  plasma
concentration of 1 μM after 1 hour and peak plasma concentration of 2 μM after 2 hours.
In humans, the plasma concentration of ~1 μM is achievable after either drinking ~8 cups
of green tea or ingestion of EGCG-rich extracts (Hirsova et al., 2012).
Bile collection and sacrifice were performed on day 9, i.e. the next day after the last
dose of EGCG. Bile collection was carried out as previously described (Hirsova et al.,
2012). Plasma and bile samples from the initial collecting period (0–30 min) were used for




2.3. Routine plasma biochemistry, bile acid and 7α-hydroxy-4-cholesten-3-one (C4)
measurements
Plasma bilirubin levels and liver enzyme activities were determined by routine laboratory
methods on Cobas Integra 800 (Roche Diagnostics). Bile acids in plasma and bile were
assayed using a commercial kit (Diazyme). Plasma concentrations of C4 were measured by
high-performance liquid chromatography (HPLC) as previously described by Lenicek et al.
(2008). The chromatographic parameters were: Tessek SGX C18 column (4 × 250 mm, 4
µm), acetonitrile:water (95:5, vol/vol) mobile phase, flow rate 1 mL/min,
detection/reference wavelength 241/360 nm. The detection limit was 1.2 µg/L.
2.4. Glutathione measurements
Concentrations of reduced (GSH) and oxidized (GSSG) glutathione were analyzed
separately using an HPLC method (Kand'ar et al., 2007) on a Shimadzu system with
fluorescence detection. The chromatographic conditions employed in the study were as
follows: stationary phase SUPELCO Discovery C18 (4 mm × 150 mm, 5 mm), mobile
phase methanol:phosphate buffer (15:85, vol/vol, 25 mM, pH 6.0), flow rate 0.5 mL/min,
detector set at 350 nm and 450 nm (excitation and emission wavelengths, respectively).
The limit of detection was 14 fmol and 5.6 fmol for GSH and GSSG, respectively. Total
glutathione was calculated as the sum of reduced and oxidized forms of glutathione.
2.5. Evaluation of paracellular permeability in the liver
We assessed hepatic tight junctional permeability by a dual-sugar test based on quantifying
biliary excretion of rhamnose and melibiose (Tomsik et al., 2008). Biliary concentrations
of melibiose and rhamnose were determined by HPLC method with a fluorescent detection
as previously described (Tomsik et al., 2008). The ratio of biliary excretion of melibiose
(disaccharide, which penetrates selectively across the paracellular junctions) to biliary
excretion of rhamnose (monosaccharide, which permeates barriers by transcellular
diffusion) was used as a marker of the blood-biliary barrier function.
2.6. Rat hepatocyte isolation, culture and treatment
Rat hepatocytes were isolated by collagenase perfusion as previously described (Kand'ar et
al., 2007) and cultured in William’s E medium supplemented with fetal bovine serum
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(10%), glutamine (2 mM), penicillin (100 IU/mL), streptomycin (10 mg/mL),
dexamethasone (0.1 µg/mL), insulin (0.08 IU/mL) and glucagon (8 ng/mL) in a collagen
sandwich  configuration.  After  24  h,  medium  was  removed  and  replaced  with  a  fresh
serum-free medium containing either DMSO or EGCG at concentrations of 1–20 µmol/L.
After 24 h incubation, cells were collected in TRI Reagent (Sigma-Aldrich) for gene
expression analysis.
2.7. Quantitative real time RT-PCR
Total RNA from rat liver and ileum were isolated with RNeasy Mini Kit (Qiagen). Total
RNA from primary rat hepatocytes was isolated using TRI Reagent (Sigma-Aldrich) and
cleaned up with RNeasy MinElute Cleanup Kit (Qiagen). Gene expression was examined
by quantitative real-time RT-PCR as previously described (Hirsova et al., 2012). TaqMan
Fast  Universal  PCR  Master  Mix  and  pre-designed  TaqMan  Gene  Expression  Assay  kits
(Supplemental Table A) were purchased from Applied Biosystems. The glyceraldehyde 3-
phosphate dehydrogenase gene was used as a reference for normalizing data.
2.8. Western blot
Protein expression in the liver was examined by Western blot as previously described
(Hirsova et al., 2012). Briefly, proteins (100 µg) were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis, transferred to a polyvinylidene difluoride membrane
(Millipore) and incubated with appropriate antibodies (Supplemental Table B).
Horseradish peroxidase-conjugated secondary antibodies were from GE Healthcare and
enhanced chemiluminescence reagents were from Thermo Pierce. Densitometry was
performed using ScanMaker i900 (UMAX) and QuantityOne imaging software (BioRad).
Protein levels were normalized to beta-actin levels.
2.9. Gene reporter assay
HepG2 cell line was purchased from the European Collection of Cell Cultures (Salisbury,
UK) and was used within 25 passages after delivery. For transient transfection gene-
reporter experiments, HepG2 cells were maintained in antibiotic-free Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum, 1% sodium pyruvate, and 1%
nonessential amino acids. HepG2 cells were co-transfected with the pGL5-luc luciferase
reporter construct, pCMX-GAL4-FXR expression plasmid containing farnesoid X receptor
ligand binding domain (Adachi et al., 2005) and pRL-TK using Lipofectamine 2000 (Life
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Technologies).  Following  24  h  of  stabilization,  HepG2 cells  were  treated  with  EGCG (5
µM and 20 µM), chenodeoxycholic acid (CDCA; 50 µM), and vehicle (DMSO; 0.1% v/v)
for 24 h. Cells were then lysed and analyzed for firefly luciferase activity normalized to the
Renilla luciferase activity (Dual-Luciferase Reporter Assay, Promega).
2.10. Statistical analysis
Data are expressed as the mean ± SD. Time-course experiments were analyzed using a
two-way analysis of variance (ANOVA) followed by Bonferroni test for post-hoc analysis.
For two-group comparison, Student’s t-test was employed. Other data were analyzed using
one-way ANOVA followed by Newman-Keuls post-hoc test. Pearson correlation
coefficients were calculated. Differences were considered significant at p-value less than
0.05. All analyses were performed using GraphPad Prism 5.0 software (San Diego, USA).
3. Results
3.1. Plasmatic markers of liver injury
Compared  to  controls,  the  sole  EGCG  administration  doubled  plasma  bile  acid
concentrations (Table 1). In contrast, EGCG did not further raise EE-elevated plasma bile
acids in EE-EGCG group. Plasma levels of bilirubin and activities of alanine transaminase
(ALT) and aspartate transaminase (AST) were not altered by EGCG treatment.
3.2. Bile flow and biliary excretion of bile acids and glutathione
To assess the effect of EGCG on bile flow, cumulative bile flow and biliary excretion of
the main bile components were calculated. Compared to controls, rats treated with EGCG
presented a significant decrease in cumulative bile flow and biliary excretion of glutathione
by 23% and 70% (p < 0.001), respectively, with no change in biliary bile acid excretion
(Fig. 1). As expected, EE decreased bile flow by both decreased biliary excretion of bile
acids and glutathione. Combination of EE and EGCG decreased bile flow and biliary bile
acid and glutathione excretion to the same extent as EE alone.
In addition, hepatic paracellular permeability (function of blood-biliary barrier) was
assessed by a dual-sugar test based on biliary excretion of melibiose and rhamnose.
Ethinylestradiol is well known to increase paracellular permeability in the liver, which
allows for the regurgitation of bile constituents into the blood (Rahner et al., 1996). Higher
ratio of biliary excretion of melibiose to rhamnose indicates increased paracellular




3.3. Expression of bile acid and glutathione transporters in the liver
To evaluate effect of EGCG at the molecular level, gene and protein expression profiles of
the major hepatic bile acid and glutathione transporters were examined in the liver by qRT-
PCR and Western blotting. EGCG administration decreased mRNA levels of Bsep, the
major  canalicular  bile  acid  efflux  transporter  (Fig.  2A),  and  Na+-taurocholate
cotransporting polypeptide (Ntcp), the major basolateral bile acid uptake transporter,  by
34% (p < 0.01) and 24% (p < 0.05), respectively. Nevertheless, their protein expression in
the liver was not changed (Fig. 2B). At the protein level, EGCG induced Mrp4 by nearly 2-
fold (p < 0.001) and reduced Mrp2 by 28% (p < 0.01). Protein expression of Mrp2 very
tightly  correlated  with  both  biliary  glutathione  excretion  (r = 0.78, p < 0.0001) and bile
flow rate (r = 0.84, p < 0.0001) (Supplemental Table C).
Similarly to previous reports (Fiorucci et al., 2005; Geier et al., 2003), EE
significantly reduced gene expression of Ntcp and organic anion transporting polypeptide
(Oatp) 1a4, and strongly upregulated Mrp3. In EE-treated group, protein expression of
Bsep, Ntcp, Oatp1a1, Oatp1a4, Mrp2 was reduced, whereas Mrp4 protein mass was
increased. EGCG coadministration to EE did not markedly change gene and protein
expression, except for the increase in Oatp1a4 mRNA and protein levels of Mrp4 and
Ntcp.
3.4. Gene expression in the ileum
Expression of key genes involved in bile acid homeostasis was evaluated in the ileum.
Individual  treatment  with  EGCG  or  EE,  as  well  as  the  combination  of  both  compounds
significantly lowered gene expression of Fgf15 and small heterodimer partner (Shp).
Similarly, all these experimental groups showed reduced expression of the main ileal bile
acid transporters, apical sodium-dependent bile salt transporter (Asbt) and organic solute
transporter (Ost) α, compared to controls (Fig. 3). On the contrary, EGCG administered to
EE-treated  rats  increased  mRNA  levels  of  Asbt,  Ostα and  Ostβ compared  to  rats
administered with EE only.
3.5. EGCG effect on bile acid synthesis
In EGCG-treated rats, hepatic expression of the rate-limiting enzyme in bile acid synthesis,
cholesterol 7α-hydroxylase (Cyp7a1), was increased by ~5 and 1.5-fold at mRNA and
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protein levels, respectively (Fig. 4A, B). Bile acid synthesis was also assessed by plasma
marker of Cyp7a1 activity, C4. The concentrations of C4 were actually doubled in EGCG-
treated rats compared to controls (Fig. 4C). We tested whether upregulation of Cyp7a1 is
reproducible in vitro in primary rat hepatocytes. EGCG at concentrations of 10 µM or
lower had no effect on mRNA expression of Cyp7a1 (Fig. 4D), whereas concentration of
20 µM increased Cyp7a1 gene expression more than 2-fold (p < 0.001).
3.6. EGCG effect on human FXR
Fusion expression construct with the ligand binding domains of human FXR fused to the
DNA binding domain of the transcription factor GAL4 was used to examine the effect of
EGCG on FXR interaction. After 24 h treatment, we did not find any activation of GAL4-
FXR construct in HepG2 treated with 5 or 20 µM EGCG (Fig.  5).  CDCA, a potent FXR
agonist, was used as a positive control in activating gene reporter construct via the pCMX-
GAL4-FXR (Adachi et al., 2005). These data suggest that EGCG may not be an activator
of human FXR in clinically relevant concentrations.
4. Discussion
The major finding of the study is that EGCG administration decreased bile production in
rats as a consequence of reduced Mrp2 protein expression and thus decreased biliary
glutathione excretion. Mrp2 is the major canalicular transporter for glutathione and various
organic anions and their metabolites conjugated with glutathione, sulfate or glucuronate.
Intracanalicular osmotic pressure generated by these compounds constitutes a bile acid-
independent mechanism of bile formation. Data from Mrp2-mutant rats have demonstrated
that absence of this protein leads to about 50% reduction in bile flow (Jemnitz et al., 2010)
and significant accumulation of its substrates (Nies and Keppler, 2007). Similar effect is
observed during blockade (e.g. cyclosporine) (Kobayashi et al., 2004) or downregulation
of  this  transporter  (Brcakova  et  al.,  2009).  Since  EGCG  had  no  effect  on  bile  acid-
dependent bile flow, the observed reduction in bile flow after EGCG treatment is very
likely a consequence of decreased Mrp2 protein. Reduced function of the Mrp2 was
confirmed by a corresponding decrease in biliary glutathione excretion. These results were
also indirectly supported by a strong positive correlation detected between bile production,
glutathione secretion and Mrp2 protein expression (Supplemental Table C). Since EGCG
has been shown to lack inhibitory effect on Mrp2 (Netsch et al., 2005), we can assume that
direct inhibition of the transporter by EGCG is likely not involved in the decreased
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glutathione excretion despite the fact that EGCG and its methyl metabolites are substrates
for human MRP2 (Hong et al., 2003) and the biliary route is the major pathway for EGCG
excretion from the body (Chen et al., 1997).
Question arising from our data is how EGCG reduces Mrp2 protein content in the
liver. Regulation of Mrp2 expression is complex and involves both transcriptional and
posttranscriptional mechanisms. The major ligand-activated transcription factor for Mrp2
is constitutive androstane receptor with a contribution of pregnane X receptor and Fxr
(Kast et al., 2002; Nies and Keppler, 2007). Posttranslational regulation is based on the
balance between the rate of protein synthesis, canalicular membrane positioning, endocytic
retrieval and degradation. Especially these later mechanisms seem to be relevant for Mrp2
regulation during various cholestatic conditions and after administration of several drugs,
including ethinylestradiol, clofibrate or dexamethasone (Johnson and Klaassen, 2002;
Micuda et al., 2008; Trauner et al., 1997; Zinchuk et al., 2005). Regarding EGCG, Li et al.
(2012) recently demonstrated ability of EGCG to activate human FXR, but not constitutive
androstane receptor, vitamin D receptor and retinoid X receptors, in the gene-reporter
assay. However, in EGCG-fed mice an increased transcription of Fxr target genes was seen
only in the intestine but not in the liver (Li et al., 2012). Our unchanged Mrp2 mRNA
levels  in  the  livers  of  EGCG-treated  animals  comply  with  this  report.  Moreover,  the
reduced Mrp2 protein mass (Fig. 2B) points towards posttranscriptional activity of the
catechin. Whether the changes are due to modified translation or impaired Mrp2 protein
turnover is not known at the present time. However, altered Mrp2 membrane trafficking or
endocytic retrieval are not likely involved since Mrp2 content in our isolated canalicular
membranes reflected the overall content of the protein (data not shown).
To  verify  the  effect  of  EGCG  on  rat  Fxr  in  the  intestine,  we  also  evaluated
expression of Asbt and Fxr target genes in the ileum: Ostα/β, Fgf15 and Shp. In
contradiction to Li et al. (2012), we have seen downregulation of these genes (Fig. 3),
which suggests Fxr alteration by EGCG at the given dose. The reported significant direct
agonistic effect of EGCG on the human FXR was also not reproduced in our settings
(Fig.5). Whether the reasons for these discrepancies are a variable accumulation of
endogenous coactivators (Li et al., 2012), gene-reporter assay differences, species
differences (mouse vs. rat vs. human) or duration of treatment (two vs. eight days) requires
further elucidation. It also raises the possibility of metabolic instability after EGCG
administration. Nevertheless, downregulation of ileal transporters essential for bile acid
absorption in EE-administered rats was described for the first time and may signify a new
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adaptive mechanism for this type of cholestasis.
An interesting finding of our study was the increased plasma concentrations of bile
acids in EGCG-treated rats. Interestingly, biliary excretion of bile acids, the major osmotic
driving force for bile formation, was not changed in this group compared to controls. Such
a situation indicates either modified enterohepatic recycling of bile acids or increased
activity  of  synthetic  enzymes.  The  major  excretory  route  for  bile  acids  from the  body is
their biliary excretion with the Bsep transporter being the rate-limiting step (Stieger, 2010).
However, neither Bsep protein expression nor protein expression of basolateral bile acid
uptake transporters (Ntcp, Oatps) were changed, which was in agreement with unchanged
biliary  excretion  of  bile  acids  after  EGCG  treatment  (Fig.  1C).  A  direct  inhibition  of
canalicular or basolateral transport of bile acids may be excluded since the clearance study
was  performed  24  hours  after  the  last  administration  of  EGCG.  Considering  that  the
reported half-life of EGCG in rats is 135 min (Chen et al., 1997) and the majority of the
drug is eliminated from the body after five half-lives, the plasma concentration of EGCG at
the time of bile collection would be too low to produce any significant inhibition of Bsep
or other transporters. The second factor that modifies excretion of bile acids is their
absorption in the ileum (Dawson et al., 2003). Annaba et al. (2010) recently indeed
demonstrated in vitro direct inhibitory effect of EGCG on sodium-dependent transport of
bile acids mediated by human ASBT, the key apical transporter for bile acid absorption in
the ileum. Therefore, we looked at the expression of this transporter in the ileum and
actually found its transcriptional downregulation, which may explain the observed increase
in fecal bile acid loss after green tea administration (Yang and Koo, 2000). As this is in
contradiction to elevated plasma bile acids after EGCG treatment, we focused on bile acid
synthesis.
In EGCG-treated rats, we detected an increased expression of Cyp7a1, the rate-
limiting enzyme in bile acid synthesis in the liver, which was further confirmed in vitro in
rat hepatocytes and by increased plasma concentrations of C4, the marker of Cyp7a1
activity (Lenicek et al., 2008). This observation is in agreement with a formerly reported
ability of EGCG to induce human CYP7A1 mRNA in HepG2 cells through increased
promoter activity of CYP7A1 (Lee et al., 2008). Because we were unable to confirm
increased activity of rat Cyp7a1 promoter by EGCG (unpublished observation), we can
suggest also another mechanism which may contribute to the induction of this enzyme
such as the downregulation of Fgf15 in intestine, which, in turn, may be followed by
disinhibition of Cyp7a1 expression in the liver (Chiang, 2009). Although the mechanism of
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EGCG action should be studied further, we may suggest that the induction of Cyp7a1 is the
main cause of EGCG-elevated plasma bile acids since the extent of plasma bile acid
increase complied with the extent of plasma C4 increase.
We tested the effect of the catechin in a model of intrahepatic cholestasis induced
by ethinylestradiol. Nevertheless, at the given dose, EGCG showed only a tendency for
further reduction in Mrp2 protein expression and biliary glutathione excretion (significant
if evaluated by Student's t-test), which was not reflected by a reduction in bile flow.
Molecular changes detected in EE-treated animals fully comply with the current concept of
this form of cholestasis (Fiorucci et al., 2005; Geier et al., 2003; Ruiz et al., 2007) and
were not modified by EGCG. Interestingly, melibiose-rhamnose permeability test revealed
a permanent impairment of blood-biliary barrier, which was modulated by neither bile duct
drainage during the bile collection nor EGCG administration. Collectively, these data
suggest that whereas the reduced bile flow (and consequently decreased intrabiliary
pressure) and decreased ileal bile acid absorption may contribute to the positive effects of
EGCG in obstructive cholestasis, a potential exacerbation of intrahepatic cholestasis by
EGCG may exist, which is warning information for long-term deliberate use of high doses
of corresponding dietary supplements.
In conclusion, EGCG is known for its protective effects in various experimental
models of liver injury. Our data, however, demonstrate that a higher dose or higher
biological availability of the catechin may raise plasma bile acid concentrations and induce
cholestasis. After exclusion of other possible mechanisms, we suggest that Cyp7a1
upregulation may stand behind or highly contribute to the increase in plasma bile acids.
The cholestatic effect of EGCG in rats is mediated by reduced Mrp2 protein expression
and thus decreased Mrp2-dependent fraction of bile flow.
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Fig. 1. Effect of EGCG on bile flow and biliary excretion. (A) EGCG and EE reduced
cumulative bile flow by 23% and 58%, respectively. (B) Permeability of blood-biliary
barrier was assessed by biliary excretion of melibiose and rhamnose. The higher ratio
indicates an increased hepatic tight junctional permeability, which was seen in both groups
receiving EE. (C) EGCG had no effect on biliary bile acid excretion. EE, either alone or in
the combination with EGCG, decreased biliary bile acid excretion to ~40% of controls. (D)
Biliary glutathione excretion declined to 30% after EGCG treatment while EE reduced this
parameter below 1%. Data are expressed as means ± SD for 6-7 animals per group.
Significantly different compared to the control group: * p < 0.05, ** p < 0.01, *** p <
0.001.
Fig. 2. Hepatic mRNA and protein levels. (A) EGCG decreased gene expression of bile
acid transporters Bsep and Ntcp. (B) Apart from Mrp2 and Mrp4, protein expression of
hepatic transporters was not altered by EGCG treatment. Data are expressed as percentage
of the average expression in the control group. Bars are means ± SD for 6-7 animals per
group. Significantly different compared to the control group: * p < 0.05, ** p < 0.01, *** p
< 0.001. Significantly different compared to EE group:  # p < 0.05, # # # p < 0.001.
Fig. 3. mRNA expression of key genes in the ileum. Levels of Fgf15, Shp, Asbt and Ostα
mRNA were downregulated in rats treated with EGCG. However, EGCG in the
combination with EE increased gene expression of Asbt, Ostα and Ostβ compared to EE
group. Data are expressed as percentage of the average expression in the control group.
Bars are means ± SD for 6-7 animals per group. Significantly different compared to the
control group: * p < 0.05, ** p < 0.01. Significantly different compared to EE group:  # p <
0.05, # # p < 0.01.
Fig. 4. Effect of EGCG on Cyp7a1 mRNA, protein, and activity. (A) EGCG upregulated
gene expression of Cyp7a1 in rat liver. (B) Protein expression of Cyp7a1 was higher in rats
treated  with  EGCG  compared  to  controls.  (C)  Rats  treated  with  EGCG  showed  a  2-fold
increase in plasma C4, the marker of Cyp7a1 activity. (D) Primary rat hepatocytes cultured
in a collagen-sandwich configuration were treated with 0, 1, 5, 10, 20 µM EGCG for 24
hours and the data presented are average from three independent experiments. EGCG at the
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concentration of 20 µM doubled Cyp7a1 gene expression in rat hepatocytes in vitro.
Significantly different compared to the control group/treatment: * p < 0.05, ** p < 0.01,
*** p < 0.001.
Fig. 5. Interaction of EGCG with human FXR. The transient transfection gene reporter
assay was performed in HepG2 cells co-transfected with the pGL5-luc luciferase reporter
construct, expression plasmid pCMX-GAL4-FXR, and pRL-TK. After 24 h, HepG2 cells
were treated with EGCG (5 µM and 20 µM), CDCA (50 µM) and vehicle of EGCG
(DMSO) for 24 h. Firefly luciferase activity was normalized to the Renilla luciferase
activity.  Data  are  shown  as  mean  fold  activation  (±  SD,  n  =  3)  of  normalized  luciferase
activity in vehicle-treated cells. Significantly different compared to the control treatment: *
p < 0.001.
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